var title_f30_10_30880="Illustration of cesarean delivery";
var content_f30_10_30880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Illustration of cesarean delivery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a c-section, the doctor makes an incision in the belly and then the uterus. The baby comes out through that incision, rather than through the vagina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30880=[""].join("\n");
var outline_f30_10_30880=null;
var title_f30_10_30881="Arthritis";
var content_f30_10_30881=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Arthritis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/10/30881/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30881/contributors\" id=\"au5833\">",
"       Robert H Shmerling, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/10/30881/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30881/contributors\" id=\"se5073\">",
"       RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/10/30881/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30881/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/10/30881?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ARTHRITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Arthritis refers to inflammation of a joint. The inflammation can affect any of the important structures inside a joint, including the joint lining (synovium), bones, cartilage, or supporting tissues. Common symptoms of arthritis include pain, stiffness, and swelling of the joint. The condition may affect one or several joints throughout the body.",
"    </p>",
"    <p>",
"     There are many possible causes of arthritis, although some are much more common than others. Some types of arthritis respond well to treatment and resolve without any lingering effects, whereas other types of arthritis are more difficult to control and can be disabling.",
"    </p>",
"    <p>",
"     This topic provides an overview of arthritis; more detailed information about the various types of arthritis is also available.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ARTHRITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     There are many possible causes of arthritis, including age-related wear and tear, infections, autoimmune conditions, injuries, and others. Topic reviews that discuss specific types of arthritis are available separately. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ARTHRITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Joint symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common symptoms of arthritis include joint pain and stiffness. There may also be joint tenderness, swelling, and limited movement of one or more joints. The skin over the joint is sometimes red.",
"    </p>",
"    <p>",
"     There are two main types of arthritis: inflammatory arthritis, which is caused by rheumatic conditions or infection, and noninflammatory arthritis, which is caused by injury, aging, or other causes. Examples of inflammatory arthritis include rheumatoid arthritis and gout. An example of noninflammatory arthritis is osteoarthritis. The location, timing, and pattern of joint pain, as well as the presence of swelling and symptoms outside the joint (such as rash), can help to distinguish between inflammatory and noninflammatory arthritis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Inflammatory arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inflammatory arthritis usually causes joint stiffness with rest, especially morning stiffness. Certain types of inflammatory arthritis, such as rheumatoid arthritis and the arthritis of systemic lupus erythematosus (SLE), affect joints on both sides of the body.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Noninflammatory arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Noninflammatory arthritis usually causes pain that is aggravated by movement and weight-bearing and is relieved by rest. Joints on one or both sides of the body may be affected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ARTHRITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The process of diagnosing arthritis involves several steps. A medical history and physical examination usually provide the most helpful information; laboratory tests, x-rays, and other tests are sometimes needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Laboratory and imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laboratory and imaging tests are sometimes, but not always, needed to determine the cause of arthritis.",
"    </p>",
"    <p>",
"     Blood tests may be recommended. For example, if rheumatoid arthritis or SLE is suspected, it can be helpful to test the blood for autoantibodies that are commonly present in these diseases.",
"    </p>",
"    <p>",
"     Testing of the fluid inside a joint, called the synovial fluid, is often helpful in determining the cause of a person's arthritis. The fluid is removed by inserting a needle inside the joint and withdrawing a sample of fluid. This procedure is sometimes called a &ldquo;joint tap.&rdquo; Analysis of the joint fluid is particularly helpful in confirming that the arthritis is inflammatory and in establishing a diagnosis of septic arthritis (due to bacterial infection), gout, or pseudogout.",
"    </p>",
"    <p>",
"     X-rays provide detailed pictures of bones. Other imaging tests, such as ultrasound, magnetic resonance imaging (MRI), and computer aided tomography (CT scan) provide images of the tissues inside and surrounding the joints. One or more of these imaging tests may be recommended to detect erosions (bone damage due to arthritis), fractures, calcium deposits, or changes in the shape of a joint.",
"    </p>",
"    <p>",
"     For many types of arthritis, changes in the joint are not visible on x-ray for months or even years. However, x-rays are often useful to monitor over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Some signs and symptoms of arthritis require urgent medical care. If you have one or more swollen joints and any of the following, you should seek medical care as soon as possible.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fever",
"      </li>",
"      <li>",
"       Weight loss",
"      </li>",
"      <li>",
"       An inability to function due to joint pain",
"      </li>",
"      <li>",
"       An overall sense of feeling ill",
"      </li>",
"      <li>",
"       Sudden weakness of specific muscle groups or",
"      </li>",
"      <li>",
"       Burning pain, numbness, or a pins-and-needles sensation",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      ARTHRITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of arthritis depends upon the specific cause. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=see_link\">",
"      \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H121\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21384988\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/23/3443?source=see_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/21/338?source=see_link\">",
"      Patient information: Ganglion cyst (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21384996\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/46/16098?source=see_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/15/34033?source=see_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/38/19045?source=see_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=see_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/0/30721?source=see_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=see_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/21/18769?source=see_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25289?source=see_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/7/3193?source=see_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=see_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=see_link\">",
"      Septic arthritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/arthritis.html\">",
"        www.nlm.nih.gov/medlineplus/arthritis.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (301) 496-8188",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Arthritis/default.asp\">",
"        www.niams.nih.gov/Health_Info/Arthritis/default.asp",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute on Aging",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nia.nih.gov/health/publication/arthritis-advice\">",
"        www.nia.nih.gov/health/publication/arthritis-advice",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (404) 633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/index.asp\">",
"        file://www.rheumatology.org/practice/clinical/patients/index.asp",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (800) 283-7800",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Arthritis Forum",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://arthritis.about.com/forum\">",
"        file://arthritis.about.com/forum",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H367050531\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     The editors of UpToDate, Inc. would like to acknowledge Robert S Pinals, MD, who contributed to earlier versions of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/10/30881?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_10_30881=[""].join("\n");
var outline_f30_10_30881=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ARTHRITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ARTHRITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ARTHRITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ARTHRITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           ARTHRITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H367050531\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30882="Osteonecrosis R hip";
var content_f30_10_30882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Osteonecrosis (avascular necrosis) of right femoral head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Plain film radiograph of the pelvis demonstrates collapse of the right femoral head (arrow) from osteonecrosis (avascular necrosis).",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30882=[""].join("\n");
var outline_f30_10_30882=null;
var title_f30_10_30883="Ranibizumab: Patient drug information";
var content_f30_10_30883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ranibizumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     see \"Ranibizumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3025066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lucentis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5376866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lucentis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macular degeneration.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2835759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macular swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702853",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ranibizumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an eye infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12053 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30883=[""].join("\n");
var outline_f30_10_30883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025066\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376866\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016123\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016122\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016127\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016128\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016130\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016125\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016126\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016132\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=related_link\">",
"      Ranibizumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30884="Excessive sebum PI";
var content_f30_10_30884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Excessive sebum production",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    How acne develops. Excessive sebum production.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30884=[""].join("\n");
var outline_f30_10_30884=null;
var title_f30_10_30885="Rimantadine: Drug information";
var content_f30_10_30885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rimantadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/11/25780?source=see_link\">",
"    see \"Rimantadine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/39/34420?source=see_link\">",
"    see \"Rimantadine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flumadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flumadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Antiviral Agent, Adamantane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of influenza A:",
"     </b>",
"     Oral: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Prophylaxis (institutional outbreak): In order to control outbreaks in institutions, if influenza A virus subtyping is unavailable and oseltamivir resistant viruses are circulating, rimantadine may be used in combination with oseltamivir if zanamivir cannot be used. Treatment should continue for &ge;2 weeks and until ~10 days after illness onset in the last patient (CDC, 2011; Harper, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of influenza A:",
"     </b>",
"     Oral: 100 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/39/34420?source=see_link\">",
"      see \"Rimantadine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of influenza A:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-9 years: 5 mg/kg/day in 1-2 divided doses; maximum: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 years and &lt;40 kg: 5 mg/kg/day in 2 divided doses (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;10 years and &ge;40 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis (institutional outbreak): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of influenza A:",
"     </b>",
"     Oral: Children &ge;17 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Prophylaxis or treatment of influenza A:",
"     </b>",
"     Oral: 100 mg daily in the elderly (&ge;65 years), including elderly nursing home patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: Dose adjustment not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 100 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F216944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Severe dysfunction: 100 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flumadine&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiation of rimantadine within 48 hours of the onset of influenza A illness halves the duration of illness and significantly reduces the duration of viral shedding and increased peripheral airways resistance; continue therapy for 5-7 days after symptoms begin; discontinue as soon as clinically warranted to reduce the emergence of antiviral drug resistant viruses",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis (adults and children &gt;1 year of age) and treatment (adults) of influenza A viral infection (per manufacturer labeling; also refer to current ACIP guidelines for recommendations during current flu season)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In certain circumstances, the ACIP recommends use of rimantadine in combination with oseltamivir for the treatment or prophylaxis of influenza A infection when resistance to oseltamivir is suspected.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rimantadine may be confused with amantadine, ranitidine, Rimactane",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flumadine&reg; may be confused with fludarabine, flunisolide, flutamide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (2% to 3%), concentration impaired (&le;2%), dizziness (1% to 2%), nervousness (1% to 2%), fatigue (1%), headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), anorexia (2%), vomiting (2%), xerostomia (2%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, ataxia, bronchospasm, cardiac failure, confusion, convulsions, depression, diarrhea, dyspnea, euphoria, gait abnormality, hallucinations, heart block, hyperkinesias, hypertension, lactation, palpitation, parosmia, pedal edema, rash, syncope, tachycardia, taste alteration, tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to drugs of the adamantine class, including rimantadine and amantadine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Influenza A: Appropriate use: Consult current guidelines. Due to increased resistance, the ACIP has recommended that rimantadine and amantadine no longer be used for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established. Rimantadine is not effective in the prevention or treatment of influenza B virus infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Avoid use, if possible, in patients with uncontrolled psychosis or severe psychoneurosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorder; an increase in seizure incidence may occur. Discontinue if seizures occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at higher risk for CNS (eg, dizziness, headache, weakness) and gastrointestinal (eg, nausea/vomiting, abdominal pain) adverse events; dosage adjustment is recommended in elderly patients &gt;65 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Resistance: May develop during treatment; viruses exhibit cross-resistance between amantadine and rimantadine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F216934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food does not affect rate or extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal data suggest embryotoxicity, maternal toxicity, and offspring mortality at doses 7-11 times the recommended human dose. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Influenza infection may be more severe in pregnant women. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Appropriate antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to influenza vaccine, or who have taken an antiviral medication during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/ not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F216926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use in nursing mothers due to potential adverse effect in infants. The CDC recommends that women infected with the influenza virus follow general precautions (eg, frequent hand washing) to decrease viral transmission to the child. Mothers with influenza-like illnesses at delivery should consider avoiding close contact with the infant until they have received 48 hours of antiviral medication, fever has resolved, and cough and secretions can be controlled. These measures may help decrease (but not eliminate) the risk of transmitting influenza to the newborn during breast-feeding. During this time, breast milk can be expressed and bottle-fed to the infant by another person who is not infected. Protective measures, such as wearing a face mask, changing into a clean gown or clothing, and strict hand hygiene should be continued by the mother for &ge;7 days after the onset of symptoms or until symptom-free for 24 hours. Infant care should be performed by a noninfected person when possible (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F216924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Flumadine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $262.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rimantadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $183.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for CNS or GI effects in elderly or patients with renal or hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gabirol (CR, DO, GT, MX, NI, SV);",
"     </li>",
"     <li>",
"      Jin Di Na (CL);",
"     </li>",
"     <li>",
"      Oclovir (AR);",
"     </li>",
"     <li>",
"      Remantadin (BG);",
"     </li>",
"     <li>",
"      Roflual (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exerts its inhibitory effect on three antigenic subtypes of influenza A virus (H1N1, H2N2, H3N2) early in the viral replicative cycle, possibly inhibiting the uncoating process; it has no activity against influenza B virus and is two- to eightfold more active than amantadine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antiviral activity: No data exist establishing a correlation between plasma concentration and antiviral effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein Binding: ~40%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 25.4 hours; prolonged in elderly, severe liver and severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;25% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Hemodialysis does not contribute to clearance",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bentley DW, Karki SD, and Betts RF, &ldquo;Rimantadine and Seizures,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1989, 110(4):323-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2011, 60(1):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/21248682/pubmed\" id=\"21248682\" target=\"_blank\">",
"        21248682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Interim Guidance: Considerations Regarding 2009 Novel H1N1 Flu Virus in Intrapartum and Postpartum Hospital Settings,\"  Available at",
"      <a href=\"file://www.cdc.gov/h1n1flu/guidance/obstetric.htm\" target=\"_blank\">",
"       file://www.cdc.gov/h1n1flu/guidance/obstetric.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/12755288/pubmed\" id=\"12755288\" target=\"_blank\">",
"        12755288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dolin R, Reichman RC, Madore HP, et al, &ldquo;A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza A Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1982, 307(10):580-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/7050702/pubmed\" id=\"7050702\" target=\"_blank\">",
"        7050702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Douglas RG Jr, &ldquo;Prophylaxis and Treatment of Influenza,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(7):443-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/2405270/pubmed\" id=\"2405270\" target=\"_blank\">",
"        2405270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Non-HIV Viral Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1994, 36(919):27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/8127252/pubmed\" id=\"8127252\" target=\"_blank\">",
"        8127252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Amantadine and Rimantadine Prophylaxis of Influenza A in Nursing Homes,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1994, 5(1):8-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/7919641/pubmed\" id=\"7919641\" target=\"_blank\">",
"        7919641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper SA, Bradley JS, Englund JA, et al, \"Expert Panel of the Infectious Diseases Society of America. Seasonal Influenza in Adults and Children -- Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(8):1003-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/19281331/pubmed\" id=\"19281331\" target=\"_blank\">",
"        19281331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MR, &ldquo;Antiviral Agents,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1992, 67(2):160-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/1347578/pubmed\" id=\"1347578\" target=\"_blank\">",
"        1347578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patriarca PA, Kater NA, Kendal AP, et al, &ldquo;Safety of Prolonged Administration of Rimantadine Hydrochloride in the Prophylaxis of Influenza A Virus Infections in Nursing Homes,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1984, 26(1):101-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/6476812/pubmed\" id=\"6476812\" target=\"_blank\">",
"        6476812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wintermeyer SM and Nahata MC, &ldquo;Rimantadine: A Clinical Perspective,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(3):299-310.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/10/30885/abstract-text/7606077/pubmed\" id=\"7606077\" target=\"_blank\">",
"        7606077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9866 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30885=[""].join("\n");
var outline_f30_10_30885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216937\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216938\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216958\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216941\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216952\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216942\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216943\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216944\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216915\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216901\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216919\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216918\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216965\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216956\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216922\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216905\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300002\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216910\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216934\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216947\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216926\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216924\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216913\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216927\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216904\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216921\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9866|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/11/25780?source=related_link\">",
"      Rimantadine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/39/34420?source=related_link\">",
"      Rimantadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30886="Clinical features and diagnosis of galactosemia";
var content_f30_10_30886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of galactosemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     V Reid Sutton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30886/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/10/30886/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactose is a sugar found primarily in human and bovine milk and milk products as part of the disaccharide lactose. Lactose is hydrolyzed to glucose and galactose by the intestinal enzyme",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    ; the galactose then is converted to glucose for use as an energy source (",
"    <a class=\"graphic graphic_figure graphicRef50614 \" href=\"mobipreview.htm?43/16/44301\">",
"     figure 1",
"    </a>",
"    ). Free galactose also is present in some fruits and vegetables, such as tomatoes, Brussels sprouts, bananas, and apples. Altered metabolism of galactose caused by deficient enzyme activity or impaired liver function results in elevated blood galactose concentration and the condition known as galactosemia.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of galactosemia will be discussed here. The management of galactosemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36950?source=see_link\">",
"     \"Management and outcome of galactosemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic galactosemia occurs in approximately 1 of 60,000 live births. However, the reported incidence of galactosemia varies geographically from 1 in 30,000 to 40,000 in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/1\">",
"     1",
"    </a>",
"    ] to 1 in 1 million in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/2\">",
"     2",
"    </a>",
"    ]. The estimated incidence in the United States is 1 in 53,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactosemia can result from deficiencies of three different enzymes (",
"    <a class=\"graphic graphic_figure graphicRef50614 \" href=\"mobipreview.htm?43/16/44301\">",
"     figure 1",
"    </a>",
"    ), each with a distinct phenotype. Impairment of galactose metabolism caused by abnormal liver function also may result in increased galactose concentrations. Impaired galactose metabolism appears to alter gene expression through epigenetic mechanisms, which may contribute to cognitive and other problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Galactose-1-phosphate uridyl transferase (GALT) deficiency &mdash; The most common and severe form of galactosemia is caused by deficiency of galactose-1-phosphate uridyl transferase (GALT), the enzyme that converts galactose-1-phosphate (galactose-1-P) to uridine diphosphate galactose (UDPgalactose) (",
"      <a class=\"graphic graphic_figure graphicRef50614 \" href=\"mobipreview.htm?43/16/44301\">",
"       figure 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Complete deficiency of GALT activity is known as classic galactosemia, often referred to by the isolated term, \"galactosemia\". Untreated patients typically have failure to thrive, liver and renal dysfunction, and sepsis; both treated and untreated patients may have cataracts, abnormal neurodevelopment, and premature ovarian failure.",
"      <br/>",
"      <br/>",
"      Partial GALT activity occurs in numerous variants; the most common of these is the Duarte variant, in which patients have one Duarte allele and one classic allele",
"      <span class=\"nowrap\">",
"       (D/G),",
"      </span>",
"      resulting in GALT activity that is approximately 5 to 25 percent of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients with two Duarte alleles",
"      <span class=\"nowrap\">",
"       (D/D)",
"      </span>",
"      have approximately 25 percent normal GALT activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients with GALT activity &ge;50 percent of normal appear to have little to no evidence of neonatal or long-term morbidity if untreated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Galactokinase (GALK) deficiency &mdash; Galactokinase is the first enzyme in the pathway of galactose metabolism, converting galactose to galactose-1-P (",
"      <a class=\"graphic graphic_figure graphicRef50614 \" href=\"mobipreview.htm?43/16/44301\">",
"       figure 1",
"      </a>",
"      ). The only consequence of galactokinase deficiency is the development of cataracts.",
"     </li>",
"     <li>",
"      Uridine diphosphate galactose 4-epimerase (GALE) deficiency &mdash; Uridine diphosphate galactose-4-epimerase (UDP galactose-4-epimerase, GALE) converts UDPgalactose to UDPglucose (",
"      <a class=\"graphic graphic_figure graphicRef50614 \" href=\"mobipreview.htm?43/16/44301\">",
"       figure 1",
"      </a>",
"      ). In most patients with GALE (or epimerase) deficiency, the defect is localized to red blood cells. These individuals typically have normal growth and development, whereas patients with generalized GALE deficiency in both red blood cells and all other tissues present with symptoms similar to classic galactosemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactosemia is an autosomal recessive disorder. More than 150 disease-causing mutations have been characterized for the GALT gene, located on chromosome 9p13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/9\">",
"     9",
"    </a>",
"    ], although a few are common. Fewer than 10 percent of mutations occur in multiple ethnic groups or geographic areas.",
"   </p>",
"   <p>",
"    The most common alleles occurring in the North American population are the following (",
"    <a class=\"graphic graphic_table graphicRef77985 \" href=\"mobipreview.htm?33/57/34715\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Q188R &mdash; Glutamine to arginine missense mutation at amino acid position 188. It is the most common classic galactosemia allele in Caucasian and Hispanic Americans.",
"     </li>",
"     <li>",
"      K285N &mdash; Lysine to asparagine missense mutation at amino acid position 285. It is a classic galactosemia allele that is a frequent occurrence in eastern Europeans.",
"     </li>",
"     <li>",
"      S135L &mdash; Serine to leucine missense mutation at amino acid position 135. It is the most common allele in African-Americans with classic galactosemia.",
"     </li>",
"     <li>",
"      N314D &mdash; Asparagine to aspartate missense mutation at amino acid position 314. It is the Duarte variant allele.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals with classic galactosemia have two classic alleles",
"    <span class=\"nowrap\">",
"     (G/G).",
"    </span>",
"    Individuals with the Duarte variant are compound heterozygotes, with one Duarte allele and one classic allele",
"    <span class=\"nowrap\">",
"     (D/G).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotype does not appear to correlate with genotype in classic galactosemia, although data are conflicting. In one study, IQ scores were lower in children homoallelic for the Q188R mutation than in those heteroallelic for Q188R with other mutations (73.6 versus 94.8), independent of sociodemographic characteristics and metabolic control (galactose-1-P levels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/10\">",
"     10",
"    </a>",
"    ]. However, in other reports, deficits in cognitive function, neurologic signs, and ovarian failure did not correlate with genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Thus, mutation analysis is not useful for prognosis or therapy in an individual with classic galactosemia.",
"   </p>",
"   <p>",
"    African-Americans may have a milder form of galactosemia, which may result from the S135L allele more common in that population. However, the milder disease also may be caused by other epigenetic (not heritable) factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Classic galactosemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic galactosemia caused by complete deficiency of GALT is the most common and severe type. Early diagnosis and treatment usually prevents or resolves the early signs and symptoms, such as liver dysfunction, susceptibility to infections, failure to thrive, and cataracts. However, despite dietary management, neuropsychological and ovarian problems occur in most adolescents and adults with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with classic galactosemia usually present in the first few days after birth and initiation of breast milk or cows' milk-based formula feedings. Specific signs and symptoms occur with different frequencies. The most common findings are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Jaundice (74 percent)",
"     </li>",
"     <li>",
"      Vomiting (47 percent)",
"     </li>",
"     <li>",
"      Hepatomegaly (43 percent)",
"     </li>",
"     <li>",
"      Failure to thrive (29 percent)",
"     </li>",
"     <li>",
"      Poor feeding (23 percent)",
"     </li>",
"     <li>",
"      Lethargy (16 percent)",
"     </li>",
"     <li>",
"      Diarrhea (12 percent)",
"     </li>",
"     <li>",
"      Sepsis (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among infants with sepsis, the most common organism is Escherichia coli sepsis (76 percent). Less frequent findings are coagulopathy, ascites, and seizures.",
"   </p>",
"   <p>",
"    On physical examination, infants typically appear jaundiced, with hepatomegaly, lethargy, and hypotonia. They may have edema and ascites, a full fontanelle, encephalopathy, and excessive bruising or bleeding.",
"   </p>",
"   <p>",
"    Lenticular cataracts may be present at birth, but generally appear after two weeks as a result of galactitol deposition in the lens. In untreated classic galactosemia and galactokinase deficiency, typically there is initial clouding of the embryonic nucleus in the central lens followed by spreading to the cortex. Occasionally, when children are not caught early, as they grow, they develop a nuclear cataract, similar to nucleus pulverulentus (derived from the Latin \"pulver\" = dust) where the nucleus of the lens looks like a cloud of dust. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of galactose-limited or galactose-free formulas may mask the initial presentation. Most states in the United States include galactosemia in newborn screening. However, affected infants may become symptomatic before the screening results become available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, clinicians must consider the diagnosis in infants with the signs and symptoms noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings of classic galactosemia include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal carbohydrate metabolism: increased plasma galactose and red blood cell (RBC) galactose-1-P concentration, increased blood and urine galactitol levels.",
"     </li>",
"     <li>",
"      Liver dysfunction: conjugated or unconjugated hyperbilirubinemia, abnormal liver function tests, coagulopathy, increased levels of plasma amino acids (especially phenylalanine, tyrosine, and methionine).",
"     </li>",
"     <li>",
"      Renal tubular dysfunction: metabolic acidosis, galactosuria (which may be indicated by the presence of reducing substances in the urine), glycosuria, aminoaciduria, albuminuria.",
"     </li>",
"     <li>",
"      Hemolytic anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Galactokinase (GALK) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consistent phenotypic feature of galactokinase deficiency is lenticular cataracts, identical to those seen in classic galactosemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/17\">",
"     17",
"    </a>",
"    ]. The cataracts usually are bilateral and resolve with dietary therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare presentation of galactokinase deficiency is pseudotumor cerebri [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/18\">",
"     18",
"    </a>",
"    ]. The mechanism is thought to be increased cerebrospinal fluid (CSF) oncotic pressure resulting from elevated CSF galactitol concentration. Clinical features of classic galactosemia typically are not present in galactokinase deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Uridine diphosphate galactose 4-epimerase (GALE) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of GALE is classically thought to be confined to erythrocytes. Affected individuals typically are asymptomatic, although erythrocyte levels of galactose-1-P are elevated. Generalized deficiency is rarely described. In one report, five children from two families with generalized epimerase deficiency had dysmorphic facial features, sensorineural deafness, poor growth, and global developmental delay, but not ovarian failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/19\">",
"     19",
"    </a>",
"    ]. However, another review of 10 patients found a spectrum of GALE activity ranging from 15 to 64 percent of control levels, suggesting that the metabolic defect is a continuum from mild (ie, red cell) to severe (ie, both red cells and lymphoblasts) impairment of galactose metabolism in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with GALE deficiency may be detected by newborn screening when states screen by measuring total galactose. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Bacterial inhibition assay to measure total galactose'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     GALT deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic galactosemia should be considered in any newborn who presents with the findings noted above (jaundice, vomiting, hepatomegaly, poor feeding, failure to thrive, lethargy, diarrhea, or sepsis). The diagnosis should be considered even in areas with neonatal screening programs because affected infants may become symptomatic before the screening results are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     RBC GALT activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration of nearly complete absence of GALT activity RBCs is the gold standard for diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13\">",
"     13",
"    </a>",
"    ]. Quantitative assay of RBC GALT activity is necessary to confirm the diagnosis; this assay also identifies variants with partial enzyme activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitative assay of RBC GALT activity may be affected for as long as three months by the transfusion of RBC from a normal donor. In such cases, DNA testing for the Q188R mutation is helpful if the patient is homozygous, but does not exclude classic galactosemia caused by other mutations. Other tests that may be helpful in transfused infants include measurement of GALT activity in the RBCs of both parents to determine whether they are carriers, and measurement of RBC galactose-1-P [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased RBC galactose-1-P concentration is a characteristic finding of classic galactosemia. The RBC galactose-1-P concentrations should not be significantly affected by RBC transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"     16",
"    </a>",
"    ]. RBC galactose-1-phosphate levels cannot accurately distinguish between partial and complete GALT deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enzyme isoelectric focusing can be a helpful adjunctive test in cases of intermediate enzyme activity levels, where ranges for Duarte galactosemia and other carrier states may overlap.",
"   </p>",
"   <p>",
"    The presence of reducing substances in the urine is neither sensitive nor specific for galactosemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"     16",
"    </a>",
"    ]. However, in a symptomatic infant, it may raise the clinical suspicion enough to trigger further evaluation and empiric treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36950?source=see_link\">",
"     \"Management and outcome of galactosemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DNA analysis is available for some of the common mutations. However, because of the large number of GALT mutations, a negative result does not exclude galactosemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal counseling should be provided before conception to parents with a family history of galactosemia or a previously affected child. Prenatal diagnosis can be made by GALT assay in fibroblasts cultured from amniotic fluid or chorionic villus biopsy or mutation analysis of DNA extracted from chorionic villus biopsy if the genotype of the index case is known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/21\">",
"     21",
"    </a>",
"    ]. When two mutations are found in a proband with classic galactosemia, carrier screening for GALT mutations is highly effective in determining risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13\">",
"     13",
"    </a>",
"    ]. Clinicians and families should also be aware that this method of testing can uncover mistaken paternity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     GALK deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;GALK deficiency should be considered in infants with lenticular cataracts. In addition, GALK deficiency should be considered in neonates who have positive bacterial inhibition newborn screens because this screen detects elevated blood galactose without distinguishing between the three potentially causative enzymes. GALK deficiency is confirmed by assay of GALK activity in RBC; the results of this assay may be affected by the transfusion of RBC from a normal donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     GALE deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;GALE deficiency should be considered in neonates who have positive bacterial inhibition newborn screens because this screen detects elevated blood galactose without distinguishing between the three potentially causative enzymes. GALE deficiency is confirmed by assay of GALE activity in RBCs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphoblasts; the results of this assay may be affected by the transfusion of RBC from a normal donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactose often is mildly elevated in normal newborns (6 to 10",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    resulting in false-positive results. Other causes of elevated galactose include liver dysfunction from conditions that include portosystemic vascular shunts, biliary atresia, and Fanconi-Bickel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     NEWBORN SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn screening programs of all states in the United States test for galactosemia. A newborn with a positive screening test for galactosemia should be changed immediately to a soy-based infant formula and the screening test should be repeated. If the second screen is positive, further testing is performed. A quantitative assay of RBC GALT confirms the diagnosis and measures the specific level of enzyme activity. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fluorometric assay of GALT enzyme activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most states use a fluorometric assay to screen for GALT enzyme activity. This assay does not depend upon the infant having been fed, but may yield false-negative results if performed within three months of a blood transfusion or false-positive results if the filter paper sample is heated inadvertently (the GALT enzyme may be inactivated by heating).",
"   </p>",
"   <p>",
"    This fluorometric method may miss compound heterozygotes for",
"    <span class=\"nowrap\">",
"     Duarte/classic",
"    </span>",
"    alleles and will not detect galactokinase or epimerase deficiency. A false-positive result may occur with glucose-6-phosphate dehydrogenase deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the fluorometric method is positive or the diagnosis is suspected despite a negative test, GALT activity should be measured and GALT",
"    <span class=\"nowrap\">",
"     electrophoresis/isoelectric",
"    </span>",
"    focusing performed. GALT",
"    <span class=\"nowrap\">",
"     electrophoresis/isoelectric",
"    </span>",
"    focusing distinguishes between normal (N), classic (G), and Duarte (D) alleles. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bacterial inhibition assay to measure total galactose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening programs in some states use a bacterial inhibition assay that detects blood galactose. In this test, elevated galactose levels inhibit bacterial growth around the filter paper blood spot after incubation in a special medium. False-negative results may occur in infants who fed poorly before the blood sample was obtained, were fed soy formula initially, or received antibiotics. If galactose levels are elevated, further testing should include an assay for GALT activity and electrophoretic mobility, and measurement of epimerase and kinase activity in RBCs. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other causes of elevated galactose are discussed above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Galactosemia can result from deficiencies of three different enzymes (",
"      <a class=\"graphic graphic_figure graphicRef50614 \" href=\"mobipreview.htm?43/16/44301\">",
"       figure 1",
"      </a>",
"      ), each with a distinct phenotype. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic galactosemia is caused by complete deficiency of galactose-1-phosphate uridyl transferase (GALT). It is an autosomal recessive disorder and occurs in approximately 1 in 60,000 live births. Infants with classic galactosemia usually present in the first few days after initiation of human breast milk or cows' milk-based feedings. Signs and symptoms include jaundice, vomiting, hepatomegaly, failure to thrive, poor feeding, lethargy, diarrhea, and sepsis (particularly due to Escherichia coli). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classic galactosemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quantitative assay of RBC GALT activity is necessary to confirm the diagnosis classic galactosemia; the results of this assay may be affected by the transfusion of RBC from a normal donor. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'GALT deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common feature of galactokinase (GALK) deficiency is lenticular cataracts. Quantitative assay of RBC GALK activity is necessary to confirm the diagnosis classic galactosemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Galactokinase (GALK) deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'GALK deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn screening for galactosemia is performed in all states in the United States. Newborns with a positive screening test for galactosemia should be changed immediately to a soy-based infant formula pending confirmation of the diagnosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Newborn screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36950?source=see_link\">",
"       \"Management and outcome of galactosemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/1\">",
"      Murphy M, McHugh B, Tighe O, et al. Genetic basis of transferase-deficient galactosaemia in Ireland and the population history of the Irish Travellers. Eur J Hum Genet 1999; 7:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/2\">",
"      Hirokawa H, Okano Y, Asada M, et al. Molecular basis for phenotypic heterogeneity in galactosaemia: prediction of clinical phenotype from genotype in Japanese patients. Eur J Hum Genet 1999; 7:757.",
"     </a>",
"    </li>",
"    <li>",
"     National Newborn Screening and Genetics Resource Center; 2002 Newborn Screening and Genetic Testing Symposium.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/4\">",
"      Coman DJ, Murray DW, Byrne JC, et al. Galactosemia, a single gene disorder with epigenetic consequences. Pediatr Res 2010; 67:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/5\">",
"      BEUTLER E, BALUDA MC, STURGEON P, DAY R. A NEW GENETIC ABNORMALITY RESULTING IN GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE DEFICIENCY. Lancet 1965; 1:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/6\">",
"      Kelley RI, Segal S. Evaluation of reduced activity galactose-1-phosphate uridyl transferase by combined radioisotopic assay and high-resolution isoelectric focusing. J Lab Clin Med 1989; 114:152.",
"     </a>",
"    </li>",
"    <li>",
"     Holton JB, Walter JH, Tyfield LA. Galactosemia. In: Metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/8\">",
"      Ficicioglu C, Thomas N, Yager C, et al. Duarte (DG) galactosemia: a pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening. Mol Genet Metab 2008; 95:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/9\">",
"      Leslie ND, Immerman EB, Flach JE, et al. The human galactose-1-phosphate uridyltransferase gene. Genomics 1992; 14:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/10\">",
"      Shield JP, Wadsworth EJ, MacDonald A, et al. The relationship of genotype to cognitive outcome in galactosaemia. Arch Dis Child 2000; 83:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/11\">",
"      Cleary MA, Heptinstall LE, Wraith JE, Walter JH. Galactosaemia: relationship of IQ to biochemical control and genotype. J Inherit Metab Dis 1995; 18:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/12\">",
"      Kaufman FR, Reichardt JK, Ng WG, et al. Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridyltransferase gene. J Pediatr 1994; 125:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/13\">",
"      Ridel KR, Leslie ND, Gilbert DL. An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol 2005; 33:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/14\">",
"      Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 1990; 13:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/15\">",
"      Segal S. Komrower Lecture. Galactosaemia today: the enigma and the challenge. J Inherit Metab Dis 1998; 21:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/16\">",
"      Walter JH, Collins JE, Leonard JV. Recommendations for the management of galactosaemia. UK Galactosaemia Steering Group. Arch Dis Child 1999; 80:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/17\">",
"      Gitzelman R. Hereditary galactokinase deficiency: a newly recognized cause of juvenile cataracts. Pediatr Res 1967; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/18\">",
"      Litman N, Kanter AI, Finberg L. Galactokinase deficiency presenting as pseudotumor cerebri. J Pediatr 1975; 86:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/19\">",
"      Walter JH, Roberts RE, Besley GT, et al. Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child 1999; 80:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/20\">",
"      Openo KK, Schulz JM, Vargas CA, et al. Epimerase-deficiency galactosemia is not a binary condition. Am J Hum Genet 2006; 78:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/21\">",
"      Jakobs C, Kleijer WJ, Allen J, Holton JB. Prenatal diagnosis of galactosemia. Eur J Pediatr 1995; 154:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/22\">",
"      Ono H, Mawatari H, Mizoguchi N, et al. Clinical features and outcome of eight infants with intrahepatic porto-venous shunts detected in neonatal screening for galactosaemia. Acta Paediatr 1998; 87:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/23\">",
"      M&uuml;ller D, Santer R, Krawinkel M, et al. Fanconi-Bickel syndrome presenting in neonatal screening for galactosaemia. J Inherit Metab Dis 1997; 20:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30886/abstract/24\">",
"      Sakura N, Mizoguchi N, Ono H, et al. Congenital biliary atresia detected as a result of galactosemia screening by the Beutler method. Clin Chim Acta 2000; 298:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2928 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30886=[""].join("\n");
var outline_f30_10_30886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genotype-phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Classic galactosemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Galactokinase (GALK) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Uridine diphosphate galactose 4-epimerase (GALE) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GALT deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - RBC GALT activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GALK deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GALE deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      NEWBORN SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fluorometric assay of GALT enzyme activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bacterial inhibition assay to measure total galactose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2928|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/16/44301\" title=\"figure 1\">",
"      Galactose metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/57/34715\" title=\"table 1\">",
"      Frequency of mutant alleles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36950?source=related_link\">",
"      Management and outcome of galactosemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30887="Molluscum pubic";
var content_f30_10_30887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30887=[""].join("\n");
var outline_f30_10_30887=null;
var title_f30_10_30888="Clinical manifestations, diagnosis, and treatment of tularemia";
var content_f30_10_30888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of tularemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Robert L Penn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30888/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/10/30888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tularemia is the zoonotic infection caused by Francisella tularensis, an aerobic and fastidious gram-negative bacterium. Human infection occurs following contact with infected animals or invertebrate vectors. The clinical manifestations from Francisella infection may range from asymptomatic illness to septic shock and death, in part depending on the virulence of the infecting strain, portal of entry, inoculum, and the immune status of the host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, treatment, and prevention of tularemia will be reviewed here. The microbiology, pathogenesis, and epidemiology of infection due to F. tularensis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average incubation period following infection with Francisella tularensis is 3 to 5 days (range 1 to 21 days). Tularemia usually has an abrupt or rapid onset of nonspecific systemic symptoms, including some combination of fever, chills, anorexia, and malaise. Patients also may complain of headache, fatigue, soreness in the chest or muscles, abdominal pain, emesis, or diarrhea. Classically the fever may abate after a few days but then quickly return.",
"   </p>",
"   <p>",
"    Additional signs and symptoms develop depending on the portal of entry; when patients come to medical attention, they usually have at least one of the six major clinical forms of tularemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ulceroglandular tularemia",
"     </li>",
"     <li>",
"      Glandular tularemia",
"     </li>",
"     <li>",
"      Oculoglandular tularemia",
"     </li>",
"     <li>",
"      Pharyngeal (oropharyngeal) tularemia",
"     </li>",
"     <li>",
"      Typhoidal tularemia",
"     </li>",
"     <li>",
"      Pneumonic tularemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some, systemic symptoms may have waned by the time the patient is evaluated. Thus, the correct diagnosis may be obscure, particularly if an exposure history or other epidemiological clues are not evident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17567759\">",
"    <span class=\"h2\">",
"     Forms of tularemia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Ulceroglandular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulceroglandular disease is the most common form of tularemia, and it is the clinical form most easily recognized as tularemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a review of 190 tularemia cases in Missouri between 2000 and 2007, ulceroglandular tularemia was the most common clinical form overall and among adults; among children, it was the second most common form (glandular disease was the most common among children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with ulceroglandular disease usually report recent animal contact, or exposure to potential insect vectors (particularly ticks). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients typically present with fever and a single erythematous papulo-ulcerative lesion with a central eschar at the site of a tick bite (",
"    <a class=\"graphic graphic_picture graphicRef51005 \" href=\"mobipreview.htm?25/51/26418\">",
"     picture 1",
"    </a>",
"    ). Tender regional lymphadenopathy may begin before, at the same time, or shortly after the appearance of the skin lesion. Occasionally more than one skin lesion may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2\">",
"     2",
"    </a>",
"    ]. Ulcers on the hands and arms are more common following animal exposures; ulcers on the head or neck, trunk, perineum, and legs are more common following tick exposures.",
"   </p>",
"   <p>",
"    Adenopathy involving cervical or occipital nodes is more common in children than adults, and the associated ulcers may be hidden in the scalp. In a series of 215 Swedish patients with infection due to the less virulent F. tularensis subspecies holarctica, erythema of the overlying skin was observed in 19 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/4\">",
"     4",
"    </a>",
"    ]. A \"sporotrichoid\" presentation, or subcutaneous nodules along the draining lymphatics, has been described in some patients with tularemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/5\">",
"     5",
"    </a>",
"    ]. However, frank lymphangitis is not usually seen; its presence should suggest bacterial superinfection of the skin ulcer.",
"   </p>",
"   <p>",
"    Patients seeking initial medical attention relatively late in the course of disease may have adenopathy with little or no fever and only evidence of a healed skin lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Glandular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glandular tularemia refers to tender regional lymphadenopathy involving single or multiple nodes, in the absence of an identifiable skin lesion. In the past it has accounted for no more than 20 percent of tularemia cases in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1\">",
"     1",
"    </a>",
"    ]. However, among 190 cases of tularemia in Missouri between 2000 and 2007, glandular disease was the most common presentation among children (44 percent of cases), and it was the second most common presentation overall (28 percent of cases); it was the third most common presentation in adults (16 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glandular disease is transmitted via the same mechanism as ulceroglandular disease, although without clinical evidence of a lesion at the site of inoculation. Consideration of the correct diagnosis may be delayed, particularly if there is little or no fever at the time of presentation. Suppurated nodes can become fluctuant, an indication for surgical or needle drainage. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The differential diagnosis of ulceroglandular and glandular tularemia is broad and includes cat scratch disease, malignancy, mycobacterial infection, syphilis, lymphogranuloma venereum, chancroid, streptococcal or staphylococcal lymphadenitis, fungal infection, toxoplasmosis, rat-bite fever, herpes simplex infection, anthrax, and plague [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280874049\">",
"    <span class=\"h3\">",
"     Oculoglandular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculoglandular tularemia accounts for a small percentage of tularemia cases. The illness is acquired when F. tularensis gains access to the conjunctiva, either via splashing infected material into the eye, rubbing eyes with contaminated fingers, or by infected aerosols. Eye symptoms may include pain, photophobia, and increased tearing. Examination of the eye demonstrates conjunctival erythema with edema and vascular engorgement. Some patients may have small conjunctival ulcers or papules, and periorbital erythema may be present. Tender regional adenopathy may be present in the preauricular, cervical, and submandibular regions. Specific complications may include corneal ulceration and dacryocystitis.",
"   </p>",
"   <p>",
"    Parinaud&rsquo;s oculoglandular syndrome refers to conjunctivitis in one eye and swollen lymph nodes in front of the ear on the same side; the causes include F. tularensis, B. henselae (cat scratch disease) and herpes simplex infection. Other items in the differential diagnosis for oculoglandular disease include adenoviral infection and pyogenic bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280874057\">",
"    <span class=\"h3\">",
"     Pharyngeal (oropharyngeal) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngeal tularemia accounts for a small percentage of cases in the United States. However, pharyngeal disease has comprised a larger percentage of cases in other parts of the world, particularly in outbreaks that have occurred as a consequence of the disruptions caused by war or natural disaster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This syndrome is the result of a primary oropharyngeal portal of infection, and is usually acquired by ingestion of contaminated food or water. Transmission can also occur from contaminated droplets or from hand to mouth following finger contamination after crushing ticks.",
"   </p>",
"   <p>",
"    The major symptoms are fever and severe sore throat. Examination demonstrates an exudative pharyngitis and tonsillitis, cervical lymph node enlargement, and usually pharyngeal or tonsillar ulcers. Preparotid and retropharyngeal lymph nodes also may be involved. Pharyngeal tularemia should be considered in patients with severe pharyngitis unresponsive to penicillin and undiagnosed after routine testing.",
"   </p>",
"   <p>",
"    The differential diagnosis includes adenoviral pharyngitis, infectious mononucleosis, and streptococcal pharyngitis. In addition, a pharyngeal membrane mimicking diphtheria may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Typhoidal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoidal tularemia is a febrile illness without prominent regional adenopathy or other localizing signs that does not fit another major form of the disease. Patients often have chronic underlying conditions, and their clinical presentation may range from acute sepsis to a chronic illness. Typhoidal disease may result from any portal of entry, and often the diagnosis is difficult to establish since relevant exposure history may be absent and the culture yield for blood and other specimens is low.",
"   </p>",
"   <p>",
"    Major symptoms include fever, chills, headache, myalgias, sore throat, diarrhea, and anorexia. Prominent physical findings may include evidence of intravascular volume depletion, mild pharyngitis, and diffuse abdominal tenderness. Enlargement of the liver and spleen is more likely to be detectable with a longer duration of illness. Pulmonary infiltrates or pleural effusion secondary to hematogenous involvement is seen in up to 45 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1\">",
"     1",
"    </a>",
"    ]. Laboratory findings in severe typhoidal tularemia may include elevated creatine phosphokinase, myoglobinuria, hyponatremia, renal failure, and F. tularensis bacteremia.",
"   </p>",
"   <p>",
"    The differential diagnosis includes Salmonella spp typhoid fever, brucellosis, Q fever, endocarditis, and the many infectious and noninfectious causes of enigmatic fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pneumonic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The illness is referred to as pneumonic tularemia when clinical manifestations of tularemia are dominated by pulmonary involvement. Pneumonic disease is more common in adults but can affect any age group and has occurred with increasing frequency. Among 190 cases in Missouri between 2000 and 2007, pneumonic disease accounted for 39 percent of adult cases and 24 percent of tularemia cases overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/3\">",
"     3",
"    </a>",
"    ]. In one series of 128 patients with tularemia, those with pneumonic disease were more likely to have underlying typhoidal illness, to recall no potential exposure, to require hospitalization, to have a longer hospital stay, to have positive cultures, and to have a higher mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/9\">",
"     9",
"    </a>",
"    ]. Pneumonic disease caused by F. tularensis subspecies tularensis (prevalent in North America) is more severe than that caused by subspecies holarctica (prevalent in other parts of the world) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link&amp;anchor=H29154667#H29154667\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary pneumonic disease results from direct inhalation of the organism into the lungs. Occupations at risk for primary disease include farmers, sheep shearers, landscapers, and laboratory workers. Initial manifestations are nonspecific, and may include headache, fever, malaise, myalgias, and anorexia. Over time, fevers and a cough with little sputum production become more pronounced, and there may be substernal or pleuritic chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/11\">",
"     11",
"    </a>",
"    ]. Findings on chest examination may include rales, signs of consolidation, and a friction rub or evidence of pleural fluid.",
"   </p>",
"   <p>",
"    Early after exposure, the chest radiograph may be normal, but it usually becomes abnormal as respiratory findings become more prominent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/11\">",
"     11",
"    </a>",
"    ]. Common radiographic changes include peribronchial infiltrates, lobar consolidation, pleural effusion, and hilar adenopathy. Rounded infiltrates and cavitation from pneumonic tularemia are uncommon, although the presence of nodular infiltrates with a pleural effusion should raise concern for tularemic pneumonia or pneumonic plague. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11512?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary pneumonic disease results from hematogenous spread to the lung. Secondary pneumonic disease is most common with typhoidal and ulceroglandular tularemia but may complicate any of the major forms of tularemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Secondary pneumonia may present with bilateral disease, involvement of the lower lobes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with miliary disease. In one series, some patients with secondary lung involvement had abnormal chest radiographs but no clinical evidence of pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural effusions in pneumonic tularemia are exudative with a lymphocytic predominance, and may have an elevated adenosine deaminase level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/12\">",
"     12",
"    </a>",
"    ]. Pleural or lung biopsies may demonstrate granuloma formation and therefore be confused with pulmonary tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Respiratory failure requiring mechanical ventilation and the adult respiratory distress syndrome may result from either primary or secondary pneumonic tularemia.",
"   </p>",
"   <p>",
"    The differential diagnosis of pneumonic tularemia includes Q fever, psittacosis, tuberculosis, pulmonary mycoses, pneumonic plague, and many other causes of community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Clinical symptoms and radiographic findings are not sufficiently specific to distinguish tularemic pneumonia from other causes of community-acquired pneumonia. The diagnosis should be considered in patients with appropriate epidemiologic exposure with a febrile illness, clinical evidence of pneumonia, negative cultures, and failure to respond to routine treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280874625\">",
"    <span class=\"h2\">",
"     Secondary skin manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary skin changes are common in tularemia and often misdiagnosed or overlooked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/4,14,15\">",
"     4,14,15",
"    </a>",
"    ]. Among children described in an outbreak in Finland, 52 percent had a secondary skin eruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/15\">",
"     15",
"    </a>",
"    ]. Secondary rashes are usually maculopapular, vesiculopapular, erythema multiforme, erythema nodosum, or urticarial. Some have been mistaken for varicella or drug eruptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with typhoidal tularemia may have erythema multiforme or erythema nodosum, while patients with pneumonic tularemia are more likely to have erythema nodosum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280874633\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently encountered complication of tularemia is lymph node suppuration. Suppurative nodes benefit from drainage even if pus is found to be sterile. In a review of tularemia cases in Missouri, 15 of 81 patients (19 percent) with lymphadenopathy required incision and drainage of suppurative nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications include sepsis, renal failure, rhabdomyolysis, and hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Empyema requiring decortication has been reported in patients with pneumonic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/16\">",
"     16",
"    </a>",
"    ]. Rarely F. tularensis infection may cause pericarditis, meningitis, osteomyelitis, peritonitis, endocarditis, or prosthetic joint infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1\">",
"     1",
"    </a>",
"    ]. One report described a patient whose only manifestation of tularemia was pericarditis; the diagnosis was made serologically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/18\">",
"     18",
"    </a>",
"    ]. Meningitis, reported with ulceroglandular and typhoidal disease, can develop 3 to 30 days after the onset of illness and cause a cerebrospinal fluid mononuclear cell pleocytosis with low glucose and high protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If untreated, tularemia may cause prolonged fever, weight loss, adenopathy, and debility that can last for weeks or months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/8\">",
"     8",
"    </a>",
"    ]. Even with appropriate treatment, some patients will have a prolonged recovery following tularemia. They often complain of fatigue and lassitude, and may have anorexia, weakness, and weight loss. Many of these patients have had suppurative lymph nodes. Risk factors for a poor outcome include older age, serious underlying disease, a delay in correct diagnosis, prolonged symptoms prior to treatment, pneumonic or typhoidal disease, renal failure, and inadequate antibiotic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/9,17\">",
"     9,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280874727\">",
"    <span class=\"h2\">",
"     Bioterrorism event",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bioterrorist attack with F. tularensis would most likely employ aerosolization of the organism to do the most harm to the most people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/20\">",
"     20",
"    </a>",
"    ]. As a result, it is expected that most patients would develop either primary pneumonic or typhoidal tularemia. Because the airborne organism also may invade through sites other than the lung and may contaminate food and water, less common presentations include oculoglandular, pharyngeal, ulceroglandular, or glandular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/13\">",
"     13",
"    </a>",
"    ]. Rapid recognition and reporting of a possible bioterrorist event due to tularemia is a difficult clinical challenge. It should be suggested by clustered cases of pneumonic or typhoidal disease, particularly in urban areas in patients without the usual exposure history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tularemia requires a high index of suspicion based on the clinical presentation and epidemiologic history. Routine laboratory tests are nonspecific. The white blood cell count may be low, normal, or elevated. Other nonspecific findings may include low platelet count, low serum sodium, abnormal liver enzymes, evidence of rhabdomyolysis or myoglobinuria, and pyuria.",
"   </p>",
"   <p>",
"    The diagnosis is usually confirmed serologically by detecting antibodies to F. tularensis using a tube agglutination or microagglutination assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/21\">",
"     21",
"    </a>",
"    ]. Tube agglutination titers are not reliably positive until after at least two weeks of illness, so they are rarely helpful in the acute setting. A single tube agglutination titer of 1:160 or higher, or a microagglutination titer of 1:128 or higher, is supportive of the diagnosis but may also result from an old infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/22\">",
"     22",
"    </a>",
"    ]. A fourfold or greater rise in titer between acute and convalescent serum specimens is usually needed for diagnostic confirmation, since antibody titers may remain elevated for years after an infection and a single elevated titer may not be specific for tularemia. A diagnostic increase in antibody titer generally occurs two to four weeks after the onset of symptoms.",
"   </p>",
"   <p>",
"    The results of serologic testing should always be interpreted in the context of the clinical suspicion for tularemia. Serologic studies should be performed only in patients in whom tularemia is a realistic possibility; they should not be used as a screening test among febrile patients.",
"   </p>",
"   <p>",
"    Gram-stained smears and tissue biopsies rarely demonstrate the organism. Routine cultures of blood, pleural fluid, skin lesions, lymph nodes, sputum, or pharynx are frequently negative since the organism is quite fastidious. In addition, most routine solid media do not contain cysteine, which many Francisella strains require for growth. However, occasionally F. tularensis has been cultured from blood and other specimens with supportive media. Therefore, the laboratory should be notified if there is a clinical suspicion for tularemia to optimize growth conditions as well as to take proper precautions to reduce the risk of infection among laboratory personnel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) has been applied successfully to the rapid diagnosis of tularemia from human specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/22\">",
"     22",
"    </a>",
"    ]. PCR assays eventually may prove to be most useful for the diagnosis of patients with several weeks of illness, and in those already given antibiotic treatment. A real-time PCR assay has been developed that can distinguish between F. tularensis subspecies tularensis types A1 and A2 infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/23\">",
"     23",
"    </a>",
"    ]. Rapid tests to detect multiple potential bioterrorism pathogens simultaneously are being explored, as are proteomic and immunologic methods for diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/13,22\">",
"     13,22",
"    </a>",
"    ]. However, at present the rapid molecular diagnosis of tularemia remains a research tool that is not generally available. In the event of a suspected bioterrorist event using F. tularensis, appropriate authorities should be contacted for assistance in sending specimens to a specialized National Public Health Network laboratory for direct visualization of the organism and other rapid diagnostic tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy should be administered to all patients in whom the diagnosis of tularemia is suspected or confirmed, even though spontaneous resolution in the absence of specific treatment may occur in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2\">",
"     2",
"    </a>",
"    ]. Early effective treatment is associated with less morbidity. Mortality from tularemia has decreased from as high as 60 percent in severely ill patients with pneumonic or typhoidal disease (prior to the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ) to less than 5 percent overall (in the antibiotic era) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/9,10,20\">",
"     9,10,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimicrobials with well-established clinical efficacy include the aminoglycosides",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , tetracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , and the fluoroquinolones. These agents exhibit achievable minimal inhibitory concentrations (MICs) when tested using a standardized in vitro method against F. tularensis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/24\">",
"     24",
"    </a>",
"    ]. However, no prospective controlled clinical trials have compared the efficacy of different drug regimens or defined the optimal duration of therapy for tularemia.",
"   </p>",
"   <p>",
"    In general, the approach to treatment is based on observational data evaluating frequency of cure and relapse with different antimicrobial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/25\">",
"     25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    remains the drug of choice for all forms of tularemia except meningitis because of its high cure rate and minimal relapses.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    is an acceptable alternative that may be administered intravenously and may be more readily available (",
"    <a class=\"graphic graphic_table graphicRef77460 \" href=\"mobipreview.htm?35/57/36764\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, once daily gentamicin dosing has been used successfully and is an option for outpatient therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/11,26\">",
"     11,26",
"    </a>",
"    ]. In general, the duration of aminoglycoside treatment is 7 to 10 days, but should be tailored to clinical signs and symptoms including resolution of fever, and may be extended to 14 days for severe cases or for patients whose response to treatment is delayed. Some authorities have recommended that severe disease other than meningitis be managed with a combination of an aminoglycoside and a fluoroquinolone, although this has not been proven to be superior to an aminoglycoside alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral agents may be used for treatment of selected patients with mild or moderate disease. Preferred agents are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef77460 \" href=\"mobipreview.htm?35/57/36764\">",
"     table 1",
"    </a>",
"    ). Observational data for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    has noted 88 percent cure rate and 12 percent relapse rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/25\">",
"     25",
"    </a>",
"    ]. The fluoroquinolones have been used successfully to treat F. tularensis subspecies holarctica infections, including in immunocompromised patients, although a higher rate of relapse was found in one small Spanish series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/7,28,29\">",
"     7,28,29",
"    </a>",
"    ]. There is less published clinical experience with using the fluoroquinolones for documented F. tularensis subspecies tularensis infections, but subspecies tularensis is susceptible to these agents in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/24\">",
"     24",
"    </a>",
"    ]. Among 14 cases of tularemia in Missouri, ciprofloxacin monotherapy achieved an 86 percent cure rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/3\">",
"     3",
"    </a>",
"    ]. Some authorities prefer fluoroquinolones over a tetracycline as oral treatment of tularemia in appropriate adults given their efficacy with lower likelihood of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/7,27\">",
"     7,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral antimicrobial therapy may be appropriate for select children with mild tularemia (",
"    <a class=\"graphic graphic_table graphicRef77460 \" href=\"mobipreview.htm?35/57/36764\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily was shown to be effective for the treatment of ulceroglandular tularemia among 12 children ages 1 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/30\">",
"     30",
"    </a>",
"    ], and its successful use has been reported in more recent cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/15\">",
"     15",
"    </a>",
"    ]. Nonetheless, fluoroquinolones are generally not recommended for treatment of tularemia in children less than 18 years of age because efficacious and potentially safer alternatives are usually available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tularemic meningitis should be managed with an aminoglycoside combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , since cerebrospinal fluid levels of aminoglycosides may be erratic.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    plus chloramphenicol was the combination reported to be successful most often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/19\">",
"     19",
"    </a>",
"    ]. Streptomycin plus doxycycline or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    plus doxycycline also have been successful combinations for meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/19\">",
"     19",
"    </a>",
"    ]. In general, the duration of treatment for tularemic meningitis is 14 to 21 days but should be tailored to clinical signs and symptoms, including resolution of fever. Chloramphenicol should not be used to treat other forms of tularemia because safer alternatives are available with greater efficacy.",
"   </p>",
"   <p>",
"    Beta-lactams have been associated with clinical failure despite favorable in vitro susceptibilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/32\">",
"     32",
"    </a>",
"    ]. Although successful use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has been reported, it is not considered reliable therapy and resistant strains are prevalent in parts of Europe and Russia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/10,22\">",
"     10,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapses may follow any regimen but are more common when tetracyclines (bacteriostatic antimicrobials) are used for less than 14 days. Should a relapse occur following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , it may be used again but for a longer period of time (such as 21 days); alternatively, the patient may be retreated with an aminoglycoside. This approach may not be effective for bioterrorism strains, however, since organisms can be engineered for resistance to commonly used agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/13,20\">",
"     13,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical management for tularemia may be required for drainage of suppurative lymph nodes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage of empyemas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard precautions are adequate for hospitalized patients with tularemia; person-to-person transmission does not occur. Microbiology laboratory and autopsy personnel should be notified whenever tularemia is suspected or proven in order to minimize the likelihood of exposure to F. tularensis.",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis for tularemia following a tick bite is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, antibiotic prophylaxis is not indicated for an individual whose only risk is having been in close contact of a patient with tularemia.",
"   </p>",
"   <p>",
"    Laboratory workers and other adults identified early in the incubation period who have had a suspected or proven high-risk exposure to tularemia should be offered either oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg twice daily for 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/20,33\">",
"     20,33",
"    </a>",
"    ]. Children may be observed for fever or other signs of illness without prophylactic antibiotics in settings other than a bioterrorist event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/33\">",
"     33",
"    </a>",
"    ]. Fluoroquinolones should not be used in children younger than 18 years of age for prophylaxis following non-bioweapon F. tularensis exposures. Doxycycline should be used in children younger than eight years of age only if the benefits of therapy exceed the risks. Observation without prophylactic antibiotics is also recommended for individuals with low-risk exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/1,20\">",
"     1,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following exposure to a F. tularensis bioweapon, all persons identified early in the incubation period should be given either oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. For adults, the recommended regimens are the same as for other high-risk exposures listed above. Dosing of doxycycline for children exposed to a F. tularensis bioweapon is 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in one or two doses daily (maximum 100 mg twice daily). Doxycycline should be used in children younger than eight years of age only if the benefits exceed the risks. Dosing of ciprofloxacin for children exposed to a F. tularensis bioweapon is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally twice daily (not to exceed 1.5 grams daily).",
"   </p>",
"   <p>",
"    Preventive measures include not using bare hands to skin or dress wild animals, avoiding sick or dead animals, wearing clothing that covers exposed skin and that is tight at the wrists and ankles, using insect repellents, removing ticks promptly, only drinking potable water, and adequately cooking wild meats.",
"   </p>",
"   <p>",
"    No tularemia vaccine is currently available. The previously used vaccine prepared from the live vaccine strain (LVS) of F. tularensis subspecies holarctica is no longer available because of concerns about its unknown mechanisms of attenuation, stability, and production. Research to develop a new vaccine is actively investigating subunit vaccines, new live strains with defined attenuation, and an improved LVS vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30888/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9834371\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typically patients with tularemia present with abrupt onset of fever, chills, headache, and malaise following an incubation period of three to five days. Additional signs and symptoms may be observed depending on the portal of entry, including&nbsp;lymphadenopathy, pharyngitis, skin",
"      <span class=\"nowrap\">",
"       ulcer/eschar/papule,",
"      </span>",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      and hepatosplenomegaly. Six major clinical syndromes (with occasional overlap) have been described in patients with Francisella infection: ulceroglandular, glandular, oculoglandular, pharyngeal, typhoidal,&nbsp;and pneumonic tularemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with tularemia present with ulceroglandular disease. Such patients usually report recent animal handling or exposure to potential insect vectors (particularly ticks). Affected patients typically present with fever and a single erythematous papulo-ulcerative lesion with a central eschar. The skin lesion is accompanied by tender regional lymphadenopathy. Patients seeking initial medical attention relatively late in the course of disease may have minimal fever and a healed skin lesion. Glandular disease involving single or multiple regional nodes in the absence of an identifiable skin lesion, although less common overall, recently has occurred more often in children than adults. Oculoglandular and pharyngeal tularemia are less common but analogous syndromes resulting from organism invasion through the conjunctivae and oral mucosa, respectively. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ulceroglandular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Glandular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H280874049\">",
"       'Oculoglandular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H280874057\">",
"       'Pharyngeal (oropharyngeal) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typhoidal tularemia is relatively uncommon; these patients present with a febrile, septic illness, with or without pneumonia. Pneumonic tularemia should be considered in patients with appropriate epidemiologic exposure and a febrile illness, clinical evidence of pneumonia, negative cultures, and failure to respond to routine treatments. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Typhoidal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pneumonic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary skin rashes are an underappreciated and relatively common manifestation of tularemia. Complications from tularemia include suppurative lymph nodes, persistent debility, sepsis, empyema, meningitis, and many other potential sites of organ involvement. (See",
"      <a class=\"local\" href=\"#H280874625\">",
"       'Secondary skin manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H280874633\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A bioterrorist attack using F. tularensis would most likely result in primary pneumonic tularemia and typhoidal tularemia; other clinical syndromes are possible but less common. Such an event should be suggested by clustered cases of pneumonic or typhoidal disease, particularly in urban areas in patients without the usual exposure history. (See",
"      <a class=\"local\" href=\"#H280874727\">",
"       'Bioterrorism event'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of tularemia requires a high index of suspicion based on the clinical presentation and epidemiologic history. The diagnosis is usually confirmed serologically. A single tube agglutination titer of 1:160 or higher, or a single microagglutination titer of 1:128 or higher, is supportive of the diagnosis; a fourfold or greater rise in titer between acute and convalescent serum specimens is usually confirmatory. A diagnostic increase in antibody titer generally occurs two to four weeks after the onset of the disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine cultures of blood, pleural fluid, skin lesions, lymph nodes, sputum, or pharynx are frequently negative since the organism is quite fastidious. The laboratory should be notified if there is a clinical suspicion of tularemia to optimize growth conditions and take proper precautions to reduce the risk of infection among laboratory personnel. In the event of a suspected bioterrorist event using F. tularensis, appropriate authorities should be contacted for assistance in sending specimens to a specialized National Public Health Network laboratory. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      for treatment of tularemia, and particularly in patients with severe disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      for treatment of selected adults with mild to moderate illness due to tularemia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      );",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      is an acceptable alternative oral agent and can be used for selected children with mild disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      for post exposure prophylaxis of individuals identified early in the incubation period following a bioterrorist event or other type of high-risk exposure to tularemia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Penn RL. Francisella tularensis (Tularemia). In: Principles and Practice of Infectious Diseases, 7th Ed, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone, Philadelphia 2010. p.2927.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/2\">",
"      Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 1985; 64:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Tularemia - Missouri, 2000-2007. MMWR Morb Mortal Wkly Rep 2009; 58:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/4\">",
"      Eliasson H, B&auml;ck E. Tularaemia in an emergent area in Sweden: an analysis of 234 cases in five years. Scand J Infect Dis 2007; 39:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/5\">",
"      Smego RA Jr, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore) 1999; 78:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/6\">",
"      Reintjes R, Dedushaj I, Gjini A, et al. Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis 2002; 8:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/7\">",
"      Meric M, Willke A, Finke EJ, et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS 2008; 116:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/8\">",
"      DIENST FT Jr. Tularemia: a perusal of three hundred thirty-nine cases. J La State Med Soc 1963; 115:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/9\">",
"      Scofield RH, Lopez EJ, McNabb SJ. Tularemia pneumonia in Oklahoma, 1982-1987. J Okla State Med Assoc 1992; 85:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/10\">",
"      Thomas LD, Schaffner W. Tularemia pneumonia. Infect Dis Clin North Am 2010; 24:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/11\">",
"      Matyas BT, Nieder HS, Telford SR 3rd. Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann N Y Acad Sci 2007; 1105:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/12\">",
"      Pettersson T, Nyberg P, Nordstr&ouml;m D, Riska H. Similar pleural fluid findings in pleuropulmonary tularemia and tuberculous pleurisy. Chest 1996; 109:572.",
"     </a>",
"    </li>",
"    <li>",
"     Hodges LS, Penn RL. Francisella tularensis (Tularemia) as an agent of tularemia. In: Principles and Practice of Infectious Diseases, 7th Ed, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone, Philadelphia 2010. p.3971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/14\">",
"      Syrj&auml;l&auml; H, Karvonen J, Salminen A. Skin manifestations of tularemia: a study of 88 cases in northern Finland during 16 years (1967-1983). Acta Derm Venereol 1984; 64:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/15\">",
"      Jounio U, Renko M, Uhari M. An outbreak of holarctica-type tularemia in pediatric patients. Pediatr Infect Dis J 2010; 29:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/16\">",
"      Weber IB, Turabelidze G, Patrick S, et al. Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases. Clin Infect Dis 2012; 55:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/17\">",
"      Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. Arch Intern Med 1987; 147:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/18\">",
"      Landais C, Levy PY, Habib G, Raoult D. Pericardial effusion as the only manifestation of infection with Francisella tularensis: a case report. J Med Case Rep 2008; 2:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/19\">",
"      Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol 2009; 66:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/20\">",
"      Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.",
"     </a>",
"    </li>",
"    <li>",
"     Lindquist D, Chu MC, Probert WS. Francisella and Brucella. In: Manual of Clinical Microbiology, 9th, Murray PR, Baron EJ, Jorgensen JG, et al.  (Eds), American Society for Microbiology Press, Washington DC 2007. Vol 1, p.815.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/22\">",
"      T&auml;rnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci 2007; 1105:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/23\">",
"      Molins CR, Carlson JK, Coombs J, Petersen JM. Identification of Francisella tularensis subsp. tularensis A1 and A2 infections by real-time polymerase chain reaction. Diagn Microbiol Infect Dis 2009; 64:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/24\">",
"      Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008; 52:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/25\">",
"      Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/26\">",
"      Hassoun A, Spera R, Dunkel J. Tularemia and once-daily gentamicin. Antimicrob Agents Chemother 2006; 50:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/27\">",
"      Eliasson H, Broman T, Forsman M, B&auml;ck E. Tularemia: current epidemiology and disease management. Infect Dis Clin North Am 2006; 20:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/28\">",
"      Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 1999; 29:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/29\">",
"      Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with ciprofloxacin. Clin Infect Dis 2000; 31:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/30\">",
"      Johansson A, Berglund L, Gothefors L, et al. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19:449.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Tularemia. In: Red Book: 2012 Report of the Committee on Infectious Diseases, Pickering LK, Baker CJ, Kimberlin DW, Long SS.  (Eds), American Academy of Pediatrics, Elk Grove, IL 2012. p.768.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/32\">",
"      Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis 1993; 17:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of tularemia among commercially distributed prairie dogs, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:688, 699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/34\">",
"      Mann BJ, Ark NM. Rationally designed tularemia vaccines. Expert Rev Vaccines 2009; 8:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/35\">",
"      El Sahly HM, Atmar RL, Patel SM, et al. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 2009; 27:4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30888/abstract/36\">",
"      Conlan JW. Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol 2011; 6:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3141 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30888=[""].join("\n");
var outline_f30_10_30888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9834371\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17567759\">",
"      Forms of tularemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Ulceroglandular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Glandular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H280874049\">",
"      - Oculoglandular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H280874057\">",
"      - Pharyngeal (oropharyngeal) disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Typhoidal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pneumonic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H280874625\">",
"      Secondary skin manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H280874633\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H280874727\">",
"      Bioterrorism event",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9834371\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3141|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/51/26418\" title=\"picture 1\">",
"      Tularemia eschar",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3141|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/57/36764\" title=\"table 1\">",
"      Antibiotics for treatment of tularemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of tularemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30889="NK cell deficiency syndromes: Clinical manifestations and diagnosis";
var content_f30_10_30889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30889/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30889/contributors\">",
"     Jordan S Orange, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30889/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30889/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30889/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/10/30889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural killer (NK) cells are non-T, non-B lymphocytes that are critical in defense against virally-infected cells and in tumor surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These cells are considered part of the innate immune system because they do not require previous exposure to foreign, pathogenic, or dangerous antigens to act.",
"   </p>",
"   <p>",
"    The importance of NK cells in human health and disease is illustrated by a small number of human diseases in which NK cells are absent or defective. These conditions are characterized primarily by severe, recurrent, or atypical infections with herpes viruses.",
"   </p>",
"   <p>",
"    The biology of NK cells, the clinical manifestations of isolated NK cell deficiency syndromes, the evaluation of patients suspected to have these disorders, and the differential diagnosis will be discussed here. The management of patients with NK cell deficiency syndromes is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4724?source=see_link\">",
"     \"NK cell deficiency syndromes: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY OF NK CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells are lymphocytes that originate in the bone marrow that comprise 5 to 10 percent of the peripheral blood lymphocyte pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/4\">",
"     4",
"    </a>",
"    ]. Although low in number, they are the main lymphocytes of the innate immune system in the peripheral blood. NK cells account for a minority of lymphocytes within organs in most cases, although there are important exceptions. In the duodenal epithelia and in the uterine decidua during pregnancy, NK cells account for up to 45 and 70 percent of lymphocytes, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Phenotypic characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells differ phenotypically from other lymphocytes by the presence of large cytoplasmic granules (",
"    <a class=\"graphic graphic_picture graphicRef76027 \" href=\"mobipreview.htm?29/50/30499\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    NK cells do not display the same cell surface markers as other populations of lymphocytes; specifically, they do not have CD3, CD4, or CD19. Instead, the majority of NK cells (although not all) display the following surface molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD2 &mdash; The receptor for the adhesion molecule for lymphocyte function associated antigen 3 (LFA-3)",
"     </li>",
"     <li>",
"      CD16 &mdash; The Fcgamma RIIIa receptor for IgG",
"     </li>",
"     <li>",
"      CD56 &mdash; A neural cellular adhesion molecule (NCAM)",
"     </li>",
"     <li>",
"      CD335 &mdash; The natural cytoxicity receptor NKp46, a specific receptor for viral hemagglutinin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, NK cells are typically characterized as CD3-,",
"    <span class=\"nowrap\">",
"     CD16/56+.",
"    </span>",
"    They are distinct from NKT cells, a subset of T lymphocytes, which are CD3+,",
"    <span class=\"nowrap\">",
"     CD16/CD56+",
"    </span>",
"    and rearrange their T cell receptor genes as do conventional T cells (see below). The major population of peripheral blood NK cells expresses intermediate levels of CD56 and is thus referred to as \"CD56dim.\" A minor population (approximately 5 percent) of NK cells in the peripheral blood has very high expression of CD56 and is referred to as \"CD56bright.\" These two subsets have important functional and developmental differences. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Immunostimulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately one-half of NK cells express CD8, although these are CD8",
"    <span class=\"nowrap\">",
"     alpha/alpha",
"    </span>",
"    homodimers, unlike the CD8",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    heterodimers expressed on cytotoxic T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Functions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important function of NK cells in the innate immune system is cellular killing, or cytotoxicity. Additional NK cell functions include cytokine and chemokine production, and costimulation of other immune cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NK cells are considered part of the innate immune response because they act through receptors that are encoded in the germline DNA and do not undergo genetic recombination to attain specificity. This distinguishes them from lymphocytes of the adaptive immune system (ie, T, B cells, and NKT cells) which recombine DNA following exposure to antigen, and generate antigen-specific T cell receptors and immunoglobulins, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/11\">",
"     11",
"    </a>",
"    ]. NK cell cytotoxicity can begin immediately and can be further induced rapidly. During an acute viral infection, increased NK cell cytotoxicity is evident within three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. In contrast, unactivated cytotoxic T lymphocytes are not capable of cytotoxicity, and once activated by viral exposure, their numbers peak approximately one week later.",
"   </p>",
"   <p>",
"    NK cells constantly survey surrounding cells for abnormalities, and rely upon the detection of various signatures of health to inhibit their potentially lethal functions. Restraining the activity of these cells are multiple families of cell-surface inhibitory receptors, of which the killer cell Ig-like receptor (KIR) family is the best characterized. These receptors are ligated by the class-I MHC molecules found on the surface of most nucleated cells, which identify the cell as \"healthy self.\" NK cell killing is inhibited if class-I MHC molecules are present in normal density. However, if class-I MHC is deficient or missing, activation receptor signaling overcomes inhibitory receptor signaling, and NK cell functions are triggered. Thus, NK cells detect and can be triggered to destroy cells that are \"missing self\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor cells and cells that are infected with certain viruses down-regulate surface class-I MHC molecules and are therefore recognized by NK cells as non-self and targeted for destruction. However, a variety of viruses have evolved to exploit this mechanism and escape NK cell-mediated defenses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As examples, some viruses encode for the expression of class-I MHC decoy molecules, while others cause selective down-regulation of those class-I MHC molecules that are most likely to engage cytotoxic T lymphocytes, while having minimal effect on the class-I MHC molecules detected by NK cells.",
"   </p>",
"   <p>",
"    KIRs signal through cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon receptor ligation, tyrosines in these ITIMs are phosphorylated, allowing the recruitment of Src homology-2 domain containing protein tyrosine phosphatases (SHP). Recruited SHPs dephosphorylate a number of cellular targets to prevent NK cell activation directed at the target cell. The most notable is Vav-1, which is a direct requirement in the signaling leading to NK cell activation and cytotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Immunostimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells serve important roles in immune responses and host defense through their ability to produce and secrete various cytokines and chemokines. NK cells are best known for their ability to secrete interferon (IFN)-gamma after activation. This enables them to participate in antiviral responses through the direct and immunostimulatory properties of this cytokine. IFN-gamma produced by NK cells is also useful in activating macrophages and facilitating their respiratory burst.",
"   </p>",
"   <p>",
"    NK cells also produce tumor necrosis factor (TNF) and under certain circumstances, interleukin (IL)-5 and IL-13. These latter two cytokines may facilitate humoral immunity, although they also suggest a possible pathogenic role for NK cells in asthma and atopic conditions.",
"   </p>",
"   <p>",
"    All NK cells can produce immunostimulatory factors; however, the CD56bright NK cells are especially effective in this role. CD56bright NK cells do not express the cytolytic machinery and mediate cytotoxicity only weakly, although these cells are potent producers of cytokines. CD56bright NK cells are also considered to be developmentally immature and have been shown to be a developmental precursor to mature CD56dim lytic effector NK cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     NK cell cytotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells can mediate the destruction of target cells based entirely upon interactions between ligands expressed by the target cell and cognate receptors present on the NK cell. This activity does not require interaction with the adaptive immune system and is also called \"natural\" or \"spontaneous\" cytotoxicity. There are numerous receptors that are capable of recognizing target cell ligands and generating signals that will result in NK cell cytotoxicity. They all require surpassing a signaling threshold set by the negative signals arising from appropriately ligated inhibitory receptors. Some activating receptors are potent in their function, while others require the cooperative efforts of multiple receptors to achieve an appropriate signaling threshold. A few of the receptors, such as 2B4 (CD244), NKG2D, and LFA-1",
"    <span class=\"nowrap\">",
"     (CD11a/CD18),",
"    </span>",
"    are involved in activation of NK cells as well as other cell types. Others are specific to NK cells, including the natural cytotoxicity receptor (NCR) family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NKp44 (CD336), which binds viral hemagglutinin",
"     </li>",
"     <li>",
"      NKp46 (CD335), which binds viral hemagglutinin",
"     </li>",
"     <li>",
"      NKp30 (CD337), which binds HLA-B-associated transcript 3 and H7-B6",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These receptors transmit intracellular signals through the immunoreceptor tyrosine-based activation motifs (ITAM) contained within a separate and required cytoplasmic signaling partner. The end result of activating receptor-driven signal cascades is usually intracellular calcium mobilization, which then enables the fusion and secretion of NK cell lytic granules with the NK cell membrane where it touches the target cell. This leads to secretion of lytic granule contents onto the target cell to promote cytotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antibody dependent cellular cytotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A well-characterized function of NK cells is antibody dependent cellular cytotoxicity (ADCC). This is a variation of NK cell cytotoxicity that cooperates with the humoral immune system to facilitate elimination of targets recognized by specific IgG.",
"   </p>",
"   <p>",
"    CD16 on the surface of the NK cell binds to the Fc portion of an IgG. IgG, in turn, is attached to a cell or organism through its antigen recognitions sites in the Fab portion. Unopposed, this interaction activates the NK cell, leading to antibody-dependent cellular cytotoxicity (ADCC) of the target cell. However, as is the case with other types of cytotoxicity receptors, activation is countered by the presence of inhibitory receptors that keep the cytotoxic functions of the cell in check.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mechanisms of killing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both NK cell cytotoxicity and ADCC involve the release of lytic granule contents, which include the pore-forming molecule perforin, as well as cell death-inducing enzymes, such as granzyme serine esterases. While some evidence suggests that some lytic molecules can enter a target cell either through a perforin pore, it is generally accepted that granzymes enter the target cell via perforin-facilitated endocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In NK cell cytotoxicity, these granules typically polarize to the portion of the NK cell that is in closest proximity to the target cell and the lytic granule contents are secreted into the space between the cells. The interface between the NK cell and target as well as the molecular arrangements that occur at that site are collectively referred to as the NK cell immunological synapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/21\">",
"     21",
"    </a>",
"    ]. The organization, maturation and function of the NK cell immunological synapse progresses in a stepwise manner and can be specifically affected by certain genetic diseases of the immune system, most notably the Congenital Hemophagocytic Syndromes (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Genetic disorders and other immunodeficiencies'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A distinct type of killing is mediated by interactions between death receptors, such as Fas on a target cell and the cognate ligand expressed on an NK cell (ie, FasL in this example). The ligation of Fas by FasL induces apoptosis in the target cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/22\">",
"     22",
"    </a>",
"    ]. The kinetics of this type of NK cell killing are slower than that mediated by perforin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CATEGORIZATION OF ISOLATED NK CELL DEFICIENCY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated NK cell deficiencies are disorders in which the",
"    <strong>",
"     only",
"    </strong>",
"    persistent immunologic deficit is that of NK cell number or function. By definition, individuals affected by these conditions do not have any other identifiable immunodeficiency disease and are not receiving medications that alter NK number or function. These disorders appear to be rare.",
"   </p>",
"   <p>",
"    The NK cell deficiency syndromes can be divided into three types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute NK cell deficiency (ANKD) &mdash; ANKD involves the complete absence of NK cells as well as the absence of activity mediated by NK cells. Patients with ANKD also lack NKT cells. A patient with very low numbers of NK cells may also be classified as having ANKD if function is absent, particularly if the few cells present were all CD56bright (the type of NK cell that is not involved in cytotoxicity).",
"     </li>",
"     <li>",
"      Classical NK cell deficiency (CNKD) &mdash; Individuals with CNKD lack NK cells and NK cell function. This condition is distinguished from ANKD by the presence of NKT cells.",
"     </li>",
"     <li>",
"      Functional NK cell deficiency (FNKD) &mdash; Individuals with FNKD possess NK cells, but have an absent or severely decreased NK cell function. Patients with FNKD usually do have NKT cells, although this is not a criterion for diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated NK cell deficiency syndromes are rare disorders. NK cell deficiency or dysfunction is characterized clinically by severe, recurrent, or atypical herpes infections (",
"    <a class=\"graphic graphic_table graphicRef50812 \" href=\"mobipreview.htm?12/23/12667\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Absolute NK cell deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute NK cell deficiency (ANKD) is defined as the complete absence of NK cells and the absence of activity mediated by NK cells. Patients with clear and convincing ANKD are rare, and most of the patients described to date have died in childhood or adolescence. The disorder demonstrates the importance of NK cells in defense against specific viral infections, including varicella zoster virus (VZV) and other herpes viruses and cytomegalovirus (CMV). Generalized Mycobacterium avium intracellulare (MAI) infection is also reported in some of these patients, perhaps due to impaired interferon-gamma production, although this has not been specifically studied. Reports of familial cases suggest there may be genetic forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports of patients with ANKD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most cited case is that of an adolescent female who presented with disseminated and life-threatening VZV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/26\">",
"       26",
"      </a>",
"      ]. She had a prior history of recurrent otitis media and intermittent leukopenia, but was otherwise well. In late adolescence, she had life-threatening systemic CMV infection followed by disseminated HSV infection. The patient had evidence of normal specific antibody production and lymphocyte responsiveness, as she had high titer IgG against VZV in her serum and her peripheral blood lymphocytes produced IFN-gamma after stimulation and demonstrated proliferation in the presence of VZV. Consistently and repeatedly, it was found that the patient did not possess CD56+ or CD16+ lymphocytes. In addition, she completely lacked NK cell cytotoxicity, even when her lymphocytes were stimulated in vitro with type-I IFN or IL-2.",
"     </li>",
"     <li>",
"      A similar phenotype was described in an adolescent male who initially presented with Salmonella enteritis and subsequently generalized MAI infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/27\">",
"       27",
"      </a>",
"      ]. In the midst of a successful antimycobacterial treatment, he died from disseminated VZV infection. He was ultimately found to lack CD56+ peripheral blood mononuclear cells (PBMC) and NK cell cytotoxic activity. Despite this, he was capable of generating specific antibody and producing IFN-gamma and IL-12, and had normal cytotoxic T cell activity.",
"     </li>",
"     <li>",
"      Another case was reported in which a previously healthy 23 month-old girl presented with severe disseminated VZV infection that resulted in her death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/28\">",
"       28",
"      </a>",
"      ]. She had normal proportions of B and T cells, as well as a proliferative response to T and B cell mitogens. Despite this, there was markedly decreased NK cytotoxicity, which could not be restored with preincubation with IL-2.",
"     </li>",
"     <li>",
"      A four year old girl with a similar phenotype also had disseminated VZV and was successfully treated using hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast to the 23 month-old, this patient also had absent B cells, and could therefore not be classified as having a pure NK cell deficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4724?source=see_link&amp;anchor=H9#H9\">",
"       \"NK cell deficiency syndromes: Treatment\", section on 'Hematopoietic cell transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial cases have been described, in which patients had undetectable NK cells and NK cell activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. This disorder is listed in the Online Mendelian Inheritance in Man database (OMIM #609981). In one report, two sisters were affected, the older of whom died from severe CMV infection. They had severe growth retardation and facial abnormalities, suggesting a syndromic immunodeficiency. They also had neutropenia and abnormalities in lymphocyte survival. The surviving sister was shown to have impaired lymphoid cell survival in response to IL-2 and IL-15 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/24\">",
"       24",
"      </a>",
"      ]. Another familial clustering occurred in large, consanguineous kindred of Irish nomadic descent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/25\">",
"       25",
"      </a>",
"      ]. One affected family member had EBV lymphoproliferation and two others had recurrent viral infections. Linkage analysis performed using multiple family members defined 8p11.23-8q11.21 as a susceptibility locus. Subsequently, the genetic defect in these individuals was defined and there are now a total of three consanguineous cohorts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. These individuals lack NK cells, but have a small number of CD56bright cells. They also have a profound somatic phenotype in that of adrenal insufficiency, and growth retardation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. These individuals demonstrated mutations in the minichromosome maintenance complex component 4 (MCM4), a DNA helicase that is involved in the unwinding and polymerization of chromosomal DNA, although how these mutations lead to the observed clinical abnormalities is not known [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Classical NK cell deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical NK cell deficiency (CNKD) is characterized by the absence of NK cells and NK cell activity, with preserved populations of NKT cells. CNKD is also rare. Case reports include a patient with severe and recurrent human papilloma virus (HPV) infection, another with extensive Trichophyton fungal infection, and a third with bilateral Epstein Barr Virus (EBV) positive smooth muscle tumors of the adrenal glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Patients had lymphocytes expressing CD56 (4 to 18 percent), but effectively none that were CD3-. Other T cell populations were normal. NK cell cytotoxicity was absent and could not be induced by IL-2 or type-I IFN stimulation in one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/34\">",
"     34",
"    </a>",
"    ]. Both patients had normal specific antibody production and lymphocyte proliferation.",
"   </p>",
"   <p>",
"    The presence of NKT cells in these patients suggests that the differentiation or survival of NK cells and NKT cells in humans is distinct. Similar to ANKD, no specific data are available regarding inheritance, but CNKD has been diagnosed in a female and thus an X-linked recessive pattern is unlikely.",
"   </p>",
"   <p>",
"    Subsequently, a large cohort of 18 patients was described, with what appears to be CNKD in the context of low numbers of monocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/36\">",
"     36",
"    </a>",
"    ]. These patients have essentially no CD56+ NK cells, but do have NKT cells. The low numbers of monocytes is intriguing, as monocytes also express CD56, albeit at low levels. Some of these cases were familial. Severe HPV infections, mycobacterial infections, and fungal infections were reported in 78, 78, and 28 percent of cases, respectively. Since, these individuals have essentially all been defined as having dominant negative mutations in the GATA2 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The mechanism linking the presumably pervasive GATA2 transcription factor to this unusual and specific immunological phenotype is presently unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Functional NK cell deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A much more common and diverse diagnosis is functional NK cell deficiency (FNKD), in which NK cells are present, but are persistently deficient in at least one of their functional activities.",
"   </p>",
"   <p>",
"    The mechanism(s) underlying this form of deficiency is largely unknown, although in a few patients, defects in the gene coding for CD16 (FcgammaRIIIa), called FCGR3A, have been identified. This is the only known single gene defect to give rise to an isolated NK cell deficiency. This mutation is informative because it connects a specific cell activity to the expression of a single gene that is relevant mainly to NK cells. CD16 is expressed on the vast majority of NK cells as well as some phagocytes. The function of CD16 on the surface of phagocytes is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CD16 mutations are described in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several individuals have been reported who are homozygous for a T to A substitution at position 230 in FCGR3A, resulting in the substitution of a histidine at position 48 in the CD16. The resulting altered protein is expressed, but the structure is abnormal and it is no longer recognized by anti-CD16 clone B73.1, although it is still recognized by other anti-CD16 antibodies, such as 3G8.",
"      <br/>",
"      <br/>",
"      The B73.1 antibody is available in the United States for clinical use, but it is not commonly used by diagnostic laboratories as a single reagent. Rather, it is used in combination with an anti-CD56 antibody, and this combination of reagents will not distinguish the altered form of CD16 from the normal form because NK cells will appear to be present based upon their normal staining with anti-CD56. However, if testing is repeated using B73.1 and 3G8 separately, the cells will appear as B73.1 negative, 3G8 positive, thus identifying the abnormal form of CD16. The author has identified several patients with this defect, all of whom had recurrent herpesvirus infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A girl homozygous for the 48H alteration suffered from frequent upper respiratory infections and severe recurrent HSV stomatitis and herpetic whitlow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/40\">",
"       40",
"      </a>",
"      ]. Interestingly, she had deficient NK cell cytotoxicity but normal antibody dependent cellular cytotoxicity (ADCC), suggesting that CD16 plays a role in IgG-independent NK cell function.",
"     </li>",
"     <li>",
"      Three other patients homozygous for the 48H phenotype and suffering from progressive or disseminated herpesvirus infections have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/41\">",
"       41",
"      </a>",
"      ]. The frequency of the CD16 48H allele may be quite high in certain populations, eg, Scandinavian Caucasians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/42\">",
"       42",
"      </a>",
"      ], and the true relation of the homozygous phenotype to the susceptibility and severity of herpesvirus disease remains a question.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other individuals appear to have FNKD without an identifiable genetic etiology, as no NK cell-specific defect could be found. These patients suffered from recurrent viral infections and severe or invasive herpesvirus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. All had otherwise normal immunologic phenotypes and normal demonstrable T cell and B cell function. None had other immunologic disorders that could potentially interfere with NK cell development, survival, or activity. In all cases, the NK cell defect was persistent in serial assessments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for an NK cell deficiency syndrome should be considered in patients with severe, recurrent, or atypical herpes infections (",
"    <a class=\"graphic graphic_table graphicRef50812 \" href=\"mobipreview.htm?12/23/12667\">",
"     table 1",
"    </a>",
"    ). It is a challenging diagnosis to make with certainty, as there are multiple known diseases and drugs that can suppress NK cell numbers or activities. Unfortunately, the possibility of an NK cell defect is raised in most cases only after a severe, debilitating, or potentially irreversible infectious disease.",
"   </p>",
"   <p>",
"    A careful medical history and a thorough physical examination are essential in the investigation of known conditions and medications that potentially impair NK cell function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    number. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluations of NK cells should include identification of NK and NKT cells and functional testing of NK cells, both ex vivo and in vitro, as outlined below and summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef60744 \" href=\"mobipreview.htm?39/9/40092\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is important to demonstrate that an NK cell deficiency or defect persists over time and is present when the patient is both infected and well. This is particularly important since acute and extreme stress or depression can transiently affect NK cell activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, the identified defect should be repeated and verified on three separate occasions, separated by at least one month each.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Identification of NK (and NKT) cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood count with differential is usually normal.",
"   </p>",
"   <p>",
"    Flow cytometry should be performed to quantify NK (CD3-,",
"    <span class=\"nowrap\">",
"     CD56/16+)",
"    </span>",
"    and NKT (CD3+,",
"    <span class=\"nowrap\">",
"     CD56/16+)",
"    </span>",
"    cells. At least two repeat assessments should be performed, ideally when the patient is free of infection or major stress, to exclude a transient deficiency, as mentioned previously. If",
"    <span class=\"nowrap\">",
"     CD56/16+",
"    </span>",
"    cells are present, then the clinician may choose to ascertain which monoclonal antibody reagent was used for detection, and obtain repeat flow cytometry with clones 3G8 and B73.1 in separate fluorescent channels to see if the CD16 variant is present (",
"    <a class=\"graphic graphic_table graphicRef60744 \" href=\"mobipreview.htm?39/9/40092\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the 3G8 antibody detects CD16, but B73.1 does not, then the variant CD16 should be suspected.",
"     </li>",
"     <li>",
"      If neither CD56 nor CD16 (using clone 3G8) are present, then the diagnoses of ANKD or CNKD should be suspected. The presence of NKT cells (CD3+,",
"      <span class=\"nowrap\">",
"       CD56/16+)",
"      </span>",
"      in CNKD distinguishes the two conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ex vivo function of NK cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step in evaluation is an ex vivo assessment of NK cell function, in the form of cytotoxicity testing. A chromium release assay is the preferred method. This testing is available through many commercial laboratories, as well as several academic centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/48\">",
"     48",
"    </a>",
"    ]. Testing should be repeated on three separate occasions, separated in time by at least one month:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If NK cells were found to be low or absent, then the patient's lymphocytes should be tested for NK cytotoxicity, which would also be expected to be severely depressed or absent, confirming the diagnosis of ANKD or CNKD.",
"     </li>",
"     <li>",
"      If NK cells were found to be low or absent, but NK cytotoxicity is present, then the patient may have a phenotypically abnormal but functional population. This is occasionally seen in some of the NK cell lymphocytoses.",
"     </li>",
"     <li>",
"      If NK cells were present, but NK cytotoxicity was severely depressed or absent, then functional NK cell deficiency is confirmed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     In vitro responsiveness of NK cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's NK cells are present, but functionally deficient, they should be stimulated with IL-2, IL-12, IFN alfa (each individually), and then assayed for cytotoxic activity, to determine whether the cytolytic defect is specific to \"natural cytotoxicity\" or affects activation-induced cytolytic functions. Testing with IL-2 also helps determine if IL-2 therapy would be potentially useful in that patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4724?source=see_link&amp;anchor=H7#H7\">",
"     \"NK cell deficiency syndromes: Treatment\", section on 'Interleukin-2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determining the mechanism underlying an NK cell deficiency syndrome requires techniques available in specialized laboratories, such as activation induced CD107a expression, granule release, conjugate formation, or others. These tests can better define deficiencies in cytolytic function and differential responses to cytokines.",
"   </p>",
"   <p>",
"    Further investigations that are mostly performed on a research basis can include detailed NK cell phenotype to determine the specific presence or absence of NK cell surface receptors that may be critical for regulation of NK cell functions, and functions mediated through specific receptors on NK cells (",
"    <a class=\"graphic graphic_table graphicRef60744 \" href=\"mobipreview.htm?39/9/40092\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation for current and past infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogens responsible for current or significant past infections should be identified whenever possible. Current infections are usually identified by culture or serologic tests. Methods of evaluating past infections include post-exposure titers, in vitro lymphocyte proliferation or cytokine production in response to pathogen or pathogen-derived antigen exposure, and cytotoxic T lymphocyte-mediated cytotoxicity against allogeneic cells infected with the suspected organism. Pathogens of the herpesvirus family are most relevant to consider and knowing the past exposure history of a potentially NK cell deficient patient can be of value in facilitating future management of illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of conditions in the differential diagnosis of the NK cell deficiency syndromes. These include acute stress, drugs and toxins, other genetic diseases and primary immunodeficiencies, autoimmune and malignant diseases, and certain infections. These other conditions may impair NK cell development, survival, or specific function.",
"   </p>",
"   <p>",
"    The most common alternative explanations for an apparent NK cell deficiency are the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incorrect usage or interpretation of laboratory tests (",
"      <a class=\"graphic graphic_table graphicRef60744 \" href=\"mobipreview.htm?39/9/40092\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suppression of NK cell function by prescribed medications (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Drugs and toxins'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Transient suppression of NK cell function by acute stress or depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Drugs and toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of medications and toxic exposures that are capable of affecting NK cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/7\">",
"     7",
"    </a>",
"    ]. In most instances, cytotoxic activity is inhibited, although the mechanism by which this occurs may be distinct in each case. Drugs and toxins affecting NK cells include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunoablative therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alcohol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Salicylates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Medications that increase cyclic AMP (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prostaglandins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cannabinoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antimalarials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Genetic disorders and other immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a surprisingly large number of genetic diseases and other primary immunodeficiency disorders that affect NK cells (",
"    <a class=\"graphic graphic_table graphicRef64501 \" href=\"mobipreview.htm?17/61/18397\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/8,57\">",
"     8,57",
"    </a>",
"    ]. These disorders may impact NK cell development, survival, or specific function.",
"   </p>",
"   <p>",
"    NK cell numbers are decreased or absent in disorders affecting NK cell development or survival. An example is severe combined immunodeficiency (SCID) due to mutation of the common gamma chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/58\">",
"     58",
"    </a>",
"    ]. This molecule is required for responsiveness to the cytokines required for NK cell development, including IL-15. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the diseases in which a gene mutation affects NK cell function are characterized by relatively normal populations of NK cells. This category is useful biologically in that genes can be linked to specific functions in NK cells. An example is familial erythrophagocytic lymphohistiocytosis due to mutation of perforin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/59\">",
"     59",
"    </a>",
"    ]. In this condition, NK cells are unable to kill target cells due to a dysfunctional perforin molecule. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous genetic diseases can involve NK cell abnormalities (",
"    <a class=\"graphic graphic_table graphicRef64501 \" href=\"mobipreview.htm?17/61/18397\">",
"     table 3",
"    </a>",
"    ). Most of these disorders have recognizable characteristics or immunologic defects of other cell types. In some of these diseases, it is accepted that an NK cell deficiency contributes to the clinical phenotype, such as in familial erythrophagocytic lymphohistiocytosis (a subtype of hemophagocytic lymphohistiocytosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/59\">",
"     59",
"    </a>",
"    ]. In others, such as the radiation hypersensitivity syndromes like Bloom syndrome, the contribution of an NK cell deficiency to the clinical course is unknown.",
"   </p>",
"   <p>",
"    Common variable immunodeficiency (CVID) is the most common primary immunodeficiency disorder that can affect NK cell function. Although only a subset of CVID cases have defects in NK cell function, CVID should be entertained in patients with isolated NK cell deficiency because of its relative frequency in the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/60\">",
"     60",
"    </a>",
"    ]. CVID is best distinguished from an NK cell deficiency by the demonstration of hypogammaglobulinemia and impaired specific antibody production. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other diseases for which NK cell deficiencies may be of clinical relevance are Chediak-Higashi syndrome, Griscelli syndrome, X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, IL-12 receptor beta 1 deficiency, and ectodermal dysplasia with immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/8,57\">",
"     8,57",
"    </a>",
"    ]. Broadly, these would include any disease that involves the potential for lymphohistiocytosis (ie, the uncontrolled accumulation of activated T-lymphocytes and macrophages in many organs) or results in an increased susceptibility to herpesvirus infection, or those with a disproportionate susceptibility to herpesviruses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=see_link\">",
"     \"Syndromic immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other diseases and infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diseases associated with NK cell deficiency include autoimmune disorders, such as rheumatoid arthritis, malignancy, and infectious diseases such as those resulting from HIV or hepatitis C virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30889/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. The precise mechanisms of these deficiencies are immunologically informative but beyond the scope of this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     NK cell biology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NK cells are non-T, non-B lymphocytes that are part of the innate immune system. They have large cytoplasmic granules (",
"      <a class=\"graphic graphic_picture graphicRef76027 \" href=\"mobipreview.htm?29/50/30499\">",
"       picture 1",
"      </a>",
"      ) and are CD3-,",
"      <span class=\"nowrap\">",
"       CD16/56+",
"      </span>",
"      upon flow cytometric analysis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Phenotypic characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NK cells produce IFN-gamma, which activates macrophages and facilitates their respiratory burst. Other prominent cytokines produced by NK cells include TNF, IL-5, and IL-13. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunostimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NK cells constantly survey surrounding cells for abnormalities and kill those cells that fail to display various signatures of health, particularly virally-infected and malignant cells. Multiple families of inhibitory receptors on the surface of NK cells, including the KIRs, act to restrain the destructive potential of these cells. NK cell cytotoxicity is rapid compared to the responses of other lymphocytes and peaks approximately three days after viral infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Functions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Mechanisms of killing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     NK cell deficiency syndromes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NK cell deficiency syndromes are rare disorders in which either the number, function, or both of NK cells is abnormal, in the absence of any other immune deficiency, medication, or other condition known to affect NK cells. These syndromes can be divided into three categories: absolute NK cell deficiency, classical NK cell deficiency, and functional NK cell deficiency. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Categorization of isolated NK cell deficiency syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NK cell disorders are characterized clinically by susceptibility to severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent infection with herpes viruses (especially VZV, HSVI and II, EBV, and CMV) (",
"      <a class=\"graphic graphic_table graphicRef50812 \" href=\"mobipreview.htm?12/23/12667\">",
"       table 1",
"      </a>",
"      ). Most of the patients reported to date have died in childhood or adolescence. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation for an NK cell deficiency syndrome should be considered in patients with severe, recurrent, or atypical infections with herpesviruses. Testing involves identification of NK and NKT cells, followed by functional testing (",
"      <a class=\"graphic graphic_table graphicRef60744 \" href=\"mobipreview.htm?39/9/40092\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flow cytometry should be performed to quantify NK (CD3-,",
"      <span class=\"nowrap\">",
"       CD56/16+)",
"      </span>",
"      and NKT (CD3+,",
"      <span class=\"nowrap\">",
"       CD56/16+)",
"      </span>",
"      cells. The presence of NKT cells in CNKD distinguishes this condition from ANKD. At least two repeat assessments of the deficiency should be performed when the patient is free of infection or major stress, to exclude a transient deficiency. The NK deficiency should then be confirmed by ex vivo cytotoxicity testing of the patient's lymphocytes, which would be expected to be absent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Identification of NK (and NKT) cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If NK cells are low or absent, then the patient's lymphocytes should be tested for NK cell function (preferably by chromium release assay), which would be expected to be accordingly low or absent, confirming the diagnosis of ANKD or CNKD. If NK cells are present, then cytotoxicity testing should be performed to evaluate their function. Absent or severely decreased function is suggestive of FNKD. Testing should be repeated on three separate occasions separated by one month each to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ex vivo function of NK cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide and varied differential diagnosis must also be considered, because many medications, diseases, and infections can alter NK cell number of function (",
"      <a class=\"graphic graphic_table graphicRef64501 \" href=\"mobipreview.htm?17/61/18397\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic testing is indicated to determine the viruses to which the patient has already been exposed, as well as those they remain at risk for contracting in the future. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation for current and past infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/1\">",
"      Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/2\">",
"      Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/3\">",
"      Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006; 118:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/4\">",
"      Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/5\">",
"      Eiras P, Rold&aacute;n E, Camarero C, et al. Flow cytometry description of a novel CD3-/CD7+ intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease. Cytometry 1998; 34:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/6\">",
"      Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol 2006; 6:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/7\">",
"      Cederbrant K, Marcusson-St&aring;hl M, Condevaux F, Descotes J. NK-cell activity in immunotoxicity drug evaluation. Toxicology 2003; 185:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/8\">",
"      Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/9\">",
"      Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/10\">",
"      Strowig T, Brilot F, M&uuml;nz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008; 180:7785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/11\">",
"      Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/12\">",
"      Biassoni R, Cantoni C, Pende D, et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001; 181:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/13\">",
"      Ljunggren HG, K&auml;rre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/14\">",
"      Orange JS, Fassett MS, Koopman LA, et al. Viral evasion of natural killer cells. Nat Immunol 2002; 3:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/15\">",
"      Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008; 8:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/16\">",
"      Stebbins CC, Watzl C, Billadeau DD, et al. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003; 23:6291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/17\">",
"      Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/18\">",
"      Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol 2005; 5:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/19\">",
"      Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007; 19:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/20\">",
"      Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007; 19:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/21\">",
"      Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/22\">",
"      Hanna J, Bechtel P, Zhai Y, et al. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 2004; 173:6547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/23\">",
"      Bernard F, Picard C, Cormier-Daire V, et al. A novel developmental and immunodeficiency syndrome associated with intrauterine growth retardation and a lack of natural killer cells. Pediatrics 2004; 113:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/24\">",
"      Eidenschenk C, Jouanguy E, Alca&iuml;s A, et al. Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. J Immunol 2006; 177:8835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/25\">",
"      Eidenschenk C, Dunne J, Jouanguy E, et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet 2006; 78:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/26\">",
"      Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/27\">",
"      Wendland T, Herren S, Yawalkar N, et al. Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia. Immunol Lett 2000; 72:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/28\">",
"      Etzioni A, Eidenschenk C, Katz R, et al. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr 2005; 146:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/29\">",
"      Notarangelo LD, Mazzolari E. Natural killer cell deficiencies and severe varicella infection. J Pediatr 2006; 148:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/30\">",
"      Hughes CR, Guasti L, Meimaridou E, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 2012; 122:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/31\">",
"      Orange JS. Unraveling human natural killer cell deficiency. J Clin Invest 2012; 122:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/32\">",
"      Gineau L, Cognet C, Kara N, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest 2012; 122:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/33\">",
"      Akiba H, Motoki Y, Satoh M, et al. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol 2001; 11:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/34\">",
"      Ballas ZK, Turner JM, Turner DA, et al. A patient with simultaneous absence of \"classical\" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset. J Allergy Clin Immunol 1990; 85:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/35\">",
"      Shaw RK, Issekutz AC, Fraser R, et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 2012; 119:4009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/36\">",
"      Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/37\">",
"      Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/38\">",
"      Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/39\">",
"      Forbes LR, Paessler M, Orange JS. CD16 deficiency discovered in a cohort of patients with severe herpesviral infections using a new diagnostic test. J Allergy Clin Immunol 2009; 123:S67 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/40\">",
"      Jawahar S, Moody C, Chan M, et al. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996; 103:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/41\">",
"      de Vries E, Koene HR, Vossen JM, et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996; 88:3022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/42\">",
"      de Haas M, Koene HR, Kleijer M, et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol 1996; 156:2948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/43\">",
"      Aoukaty A, Lee IF, Wu J, Tan R. Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells. J Clin Immunol 2003; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/44\">",
"      Fleisher G, Starr S, Koven N, et al. A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr 1982; 100:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/45\">",
"      Lopez C, Kirkpatrick D, Read SE, et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J Infect Dis 1983; 147:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/46\">",
"      Komiyama A, Kawai H, Yabuhara A, et al. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Pediatrics 1990; 85:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/47\">",
"      Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     Academic centers include the University of Iowa, Cincinnati Children's Hospital, and Children's Hospital of Philadelphia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/49\">",
"      Nair MP, Schwartz SA. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol 1984; 132:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/50\">",
"      Botzler C, Kis K, Issels R, Multhoff G. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets. Exp Hematol 1997; 25:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/51\">",
"      Nair MP, Kronfol ZA, Schwartz SA. Effects of alcohol and nicotine on cytotoxic functions of human lymphocytes. Clin Immunol Immunopathol 1990; 54:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/52\">",
"      Knight SC, Harding B, Burman S, Mertin J. Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression. Clin Exp Immunol 1981; 46:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/53\">",
"      Roder JC, Klein M. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol 1979; 123:2785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/54\">",
"      Hall TJ, Chen SH, Brostoff J, Lydyard PM. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol 1983; 54:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/55\">",
"      Specter S, Rivenbark M, Newton C, et al. Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. Int J Immunopharmacol 1989; 11:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/56\">",
"      Ausiello CM, Barbieri P, Spagnoli GC, et al. In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin Exp Rheumatol 1986; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/57\">",
"      Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002; 4:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/58\">",
"      Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/59\">",
"      Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/60\">",
"      Koren HS, Amos DB, Buckley RH. Natural killing in immunodeficient patients. J Immunol 1978; 120:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/61\">",
"      Russell AS, Miller C. The activity of natural killer cells in patients with rheumatoid arthritis: I. The effect of drugs used in vivo. Clin Exp Rheumatol 1984; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/62\">",
"      Fujimiya Y, Bakke A, Chang WC, et al. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1. Int J Cancer 1986; 37:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/63\">",
"      Ullum H, G&oslash;tzsche PC, Victor J, et al. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J Exp Med 1995; 182:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30889/abstract/64\">",
"      Corado J, Toro F, Rivera H, et al. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 109:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3949 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30889=[""].join("\n");
var outline_f30_10_30889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY OF NK CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Phenotypic characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Functions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Immunostimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - NK cell cytotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antibody dependent cellular cytotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mechanisms of killing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CATEGORIZATION OF ISOLATED NK CELL DEFICIENCY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Absolute NK cell deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Classical NK cell deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Functional NK cell deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Identification of NK (and NKT) cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ex vivo function of NK cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - In vitro responsiveness of NK cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation for current and past infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Genetic disorders and other immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other diseases and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NK cell biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NK cell deficiency syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3949|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/50/30499\" title=\"picture 1\">",
"      NK cell electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/23/12667\" title=\"table 1\">",
"      NK deficiency syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/9/40092\" title=\"table 2\">",
"      Approach to the diagnosis of NK cell deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/61/18397\" title=\"table 3\">",
"      Genetic diseases with NK def",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4724?source=related_link\">",
"      NK cell deficiency syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=related_link\">",
"      Syndromic immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30890="Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction";
var content_f30_10_30890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/10/30890/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/10/30890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death from a ventricular tachyarrhythmia in the setting of an acute myocardial infarction (MI) has historically been one of the most frequent causes of sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a 1985 report, for example, 60 percent of deaths associated with acute MI occurred within the first hour and were attributable to a ventricular arrhythmia, in particular ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/3\">",
"     3",
"    </a>",
"    ]. However, subsequent improvements in arrhythmia detection and treatment have had a major impact on the outcome of ventricular arrhythmias associated with acute MI. As a result, both arrhythmic and overall in-hospital mortality from acute myocardial infarction (MI) have fallen significantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41769?source=see_link\">",
"     \"Prognosis after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence, clinical features, and treatment of ventricular tachyarrhythmias associated with acute MI will be reviewed here. Risk stratification for life-threatening ventricular arrhythmias after MI, prophylactic treatment of ventricular arrhythmias following MI, and the management of ventricular arrhythmias in the setting of chronic coronary heart disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3618811\">",
"    <span class=\"h2\">",
"     Pre-fibrinolytic era versus PCI era",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many studies have evaluated the incidence of ventricular arrhythmias in the peri-infarct period, comparison of these studies is difficult due to differences in populations (percutaneous intervention therapy versus fibrinolytic therapy versus no therapy), type of infarct (ST segment elevation MI versus non-ST segment elevation MI versus both) and arrhythmia reported (ventricular tachycardia versus VF versus both).",
"   </p>",
"   <p>",
"    Ventricular arrhythmias, ranging from isolated ventricular premature beats to ventricular fibrillation, are common in the immediate postinfarction period. Observations in the pre-fibrinolytic era found the following range of incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular premature beats (VPBs) &ndash; 10 to 93 percent",
"     </li>",
"     <li>",
"      Ventricular tachycardia (VT) &ndash; 3 to 39 percent",
"     </li>",
"     <li>",
"      Ventricular fibrillation (VF) &ndash; 4 to 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the era of early percutaneous intervention, VT (especially non-sustained VT) remains fairly common. In the MERLIN-TIMI 36 study of 6355 patients with non-ST elevation acute coronary syndromes who underwent seven days of continuous electrocardiographic (ECG) monitoring following their presentation to the hospital to assess for VT and ischemia, 25.3 percent were found to have VT (20 percent VT without ischemia, 5.3 percent VT with ischemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/9\">",
"     9",
"    </a>",
"    ]. Compared to patients with neither VT nor ischemia on continuous ECG monitoring, patients with VT without concurrent ischemia had a significantly increased risk of both cardiovascular death and sudden cardiac death (adjusted hazard ratio [HR] 2.2 and 2.3, respectively). Patients with VT and ischemia had an even higher risk of both cardiovascular death and sudden cardiac death (adjusted HR 5.4 and 6.5, respectively).",
"   </p>",
"   <p>",
"    Early series underestimated the incidence of unstable VT and VF, because they did not include patients whose MI resulted in out-of-hospital sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of ventricular arrhythmias appears to be higher with ST elevation (Q wave) than non-ST elevation (non-Q wave) infarctions (STEMI and NSTEMI).",
"   </p>",
"   <p>",
"    VT is less common than VF in the periinfarction period. This is probably due to the fact that VT usually requires a reentrant circuit and a fixed arrhythmic substrate, such as the scar from a healed MI. When VT occurs during an acute MI, it may reflect triggered activity, enhanced automaticity, or a prior infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the incidence of ventricular arrhythmias at the time of acute STEMI come from studies of patients treated with either fibrinolysis or primary percutaneous coronary intervention (PCI). Although the incidence of ventricular arrhythmias is probably lower with contemporary therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/11-16\">",
"     11-16",
"    </a>",
"    ], these data also probably underestimate the true incidence of arrhythmias because patients with pre-hospital sudden cardiac death may not have been included in studies of fibrinolysis or primary PCI. The risk factors for and the prognosis of early VT or VF in patients with STEMI are discussed separately. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Prognosis after early VT'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Prognosis after early VF'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with acute MI in the fibrinolytic era, the incidence of VF has ranged from 3.7 to 6.7 percent in large studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13-18\">",
"     13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest experience in patients (40,895) with acute STEMI treated with fibrinolytic therapy comes from the GUSTO-1 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14\">",
"     14",
"    </a>",
"    ]. The overall incidence of sustained VT or VF was 10.2 percent (3.5 percent developed VT, 4.1 percent VF, and 2.7 percent both VT and VF). Approximately 80 to 85 percent of these arrhythmias occurred in the first 48 hours.",
"   </p>",
"   <p>",
"    A similar frequency of VF was noted in a report from the GISSI-2 database of 9720 patients with a first MI treated with a fibrinolytic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early (&le;4 hours) primary VF (ie, VF in the absence of heart failure or shock) occurred in 3.1 percent. VF recurred during the hospitalization in 11 percent of these patients.",
"     </li>",
"     <li>",
"      Late VF (&gt;4 to 48 hours) occurred in 0.6 percent and was recurrent in 15 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two problems with fibrinolytic trials bring into question the validity of their reported arrhythmia incidence. First, by nature of their patient inclusion and consent issues, patients who died of SCD in the prehospital arena were excluded from the trial denominator. Secondly, fibrinolysis and reperfusion may lead to reperfusion arrhythmias, falsely increasing the incidence of MI associated arrhythmias. Given the reduced incidence of VT and VF compared to older studies, it seems likely that reperfusion does not necessarily increase the overall incidence of VF or sustained VT. Ventricular premature beats (VPBs) and accelerated idioventricular rhythm (AIVR) have been thought to be a marker of reperfusion following fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\", section on 'Reperfusion arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among 5745 STEMI patients with planned percutaneous coronary intervention (PCI) enrolled in the APEX AMI trial, VT or VF occurred in 329 (5.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/20\">",
"     20",
"    </a>",
"    ]. The arrhythmia was noted before catheterization in 25, during catheterization in 180, and after catheterization but before discharge in 170 patients. Most events (282) occurred within the first 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Non-ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data on the incidence of sustained ventricular arrhythmias in patients with acute NSTEMI or unstable angina comes from a pooled analysis of four major trials of over 25,000 patients with a non-ST elevation acute coronary syndrome (NSTEMI or unstable angina) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/15\">",
"     15",
"    </a>",
"    ]. The overall incidence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) was 2.1 percent, which is lower than the 10.2 percent STEMI incidence in GUSTO-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14\">",
"     14",
"    </a>",
"    ]. VT occurred in 0.8 percent, VF in 1 percent, and VT and VF in 0.3 percent. The median time to arrhythmia was 78 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Temporal trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence regarding changes in the incidence of ventricular fibrillation (VF) with advancements in care for acute MI. One series showed no difference in the incidence between 1975 and 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/3\">",
"     3",
"    </a>",
"    ], while a second report noted a reduction in nonprimary VF, but no change in primary VF (ie, VF in the absence of heart failure or shock), between 1979 and 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/16\">",
"     16",
"    </a>",
"    ]. Improvements in therapy have led to a reduction in the in-hospital mortality in those who develop VF from approximately 50 percent in 1975 to 20 percent in 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FAMILIAL PREDISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be inherited factors that predispose some individuals to ventricular arrhythmias and sudden cardiac death (SCD) in the setting of an MI. This possibility was supported by two case-control studies in slightly different populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients presenting with a first ST elevation MI, 330 survivors of primary VF (ie, VF in the absence of heart failure or shock) were compared to 372 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/21\">",
"       21",
"      </a>",
"      ]. A family history of SCD was more common among those who experienced primary VF (odds ratio 2.7, 95% confidence interval 1.8 to 4.0, compared to controls).",
"     </li>",
"     <li>",
"      In a Finnish series of consecutive SCD victims who underwent autopsy (which is mandatory for unexplained SCD in Finland), 138 were identified who had an acute coronary event, but no history of prior MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/22\">",
"       22",
"      </a>",
"      ]. These cases were compared to two control groups; 254 consecutive patients surviving an acute MI, and 470 healthy subjects. A history of SCD in first-degree relatives was ascertained in each group. The incidence of SCD was significantly higher in the relatives of SCD victims than in those of the acute MI survivors or the control subjects (5.6, 3.3, and 1.6 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these observations are intriguing, this study design is subject to the possibility of recall bias, which could lead to an overestimation of the familial risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11046610\">",
"    <span class=\"h1\">",
"     VENTRICULAR PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ventricular premature beats (VPBs) after acute MI is associated with an increased total mortality in some patients, particularly those with larger infarctions and impaired left ventricular function. It is uncertain if the increased risk is attributable to VPBs alone or only to repetitive forms, which often occur in association with frequent VPBs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11046617\">",
"    <span class=\"h2\">",
"     Pre-thrombolytic era",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the widespread use of thrombolytic therapy for treatment of acute ST elevation myocardial infarction (STEMI), a number of reports found that repetitive ventricular premature beats (VPBs), but not frequent VPBs alone, were associated with an increased risk among post-MI patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. In the largest of these series, the prognostic significance of VPBs detected in a one hour electrocardiogram monitoring session was evaluated in 1739 men with a recent MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/23\">",
"     23",
"    </a>",
"    ]. At a mean follow-up of two years, patients with ventricular bigeminy, couplets, or multiform VPBs had a three-fold increase in sudden death and a two-fold increase in all-cause mortality. In comparison, this was not noted in those who had only simple VPBs, regardless of frequency. The increase in risk persisted at later follow-up at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, other studies have found that an increased frequency of VPBs alone may be associated with an increased mortality risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. As an example, the European Infarction Study Group noted a 4 percent two-year mortality in post-MI patients with more than 10 VPBs per hour, a value significantly higher than in that seen in those with no or fewer VPBs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/28\">",
"     28",
"    </a>",
"    ]. The two-year mortality was much greater in patients with ventricular couplets (22 and 10 percent if more than ten and one to nine couplets per day, respectively).",
"   </p>",
"   <p>",
"    There are also conflicting data as to whether the effect of VPBs upon sudden death in post-MI patients is independent of left ventricular dysfunction. It is possible, for example, that VPBs may only signify the presence of a severe myocardial process and may not be an independent provoker of a terminal electrical event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/30\">",
"     30",
"    </a>",
"    ]. However, although a relationship exists between the frequency of ventricular arrhythmias and the degree of left ventricular dysfunction, the results of several large well-designed studies have found that an increased frequency of complex VPBs is an important risk factor independent of the degree of myocardial damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/25,31,32\">",
"     25,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11046624\">",
"    <span class=\"h2\">",
"     Thrombolytic era",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of patients with an ST elevation myocardial infarction (STEMI) treated in the thrombolytic era have also noted an increased mortality rate associated with ventricular premature beats (VPB) in the post infarction period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review from the GISSI-2 trial evaluated 8676 patients with STEMI treated with thrombolytic therapy undergoing 24-hour Holter monitoring before discharge: 64 percent had at least one VPB per hour and 20 percent had more than 10 VPBs per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/33\">",
"     33",
"    </a>",
"    ]. At six months, the mortality rate was 5.5 percent in patients with more than 10 VPBs per hour compared to 2.0 and 2.7 percent in patients without ventricular arrhythmia or with 1 to 10 VPBs per hour, respectively. After adjusting for risk factors, more than 10 VPBs per hour remained a significant predictor for both total (relative risk 1.62, 95% CI 1.16-2.26) and sudden mortality (RR 2.24, 95% CI 1.22-4.08).",
"   </p>",
"   <p>",
"    As in the prethrombolytic era, it is uncertain if the increase in risk after thrombolysis is attributable to VPBs themselves or to the presence of repetitive forms that occur in association with frequent VPBs. In the GISSI-2 analysis, the presence of complex VPBs and the occurrence of more than 10 VPBs per hour were associated with a similar six-month mortality (4.8 and 5.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings were different in the Canadian Assessment of Myocardial Infarction (CAMI) study, which included 3178 patients with either an STEMI or a non-ST elevation myocardial infarction (NSTEMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/36\">",
"     36",
"    </a>",
"    ]. Although cardiac mortality increased progressively with increasing frequency of VPBs, VPBs alone had no independent predictive value in multivariate analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11046631\">",
"    <span class=\"h2\">",
"     Primary PCI era",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very limited data have been published assessing VPBs following primary percutaneous coronary intervention (PCI). One single-center study of 44 consecutive STEMI patients treated with primary PCI measured the frequency of VPBs in the first 24 hours post-PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/37\">",
"     37",
"    </a>",
"    ]. Compared to historical controls treated with thrombolysis, no significant difference was seen in the frequency of VPBs in the initial 24 hours post-PCI, although there was a trend toward fewer VPBs in the patients treated with PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11047053\">",
"    <span class=\"h2\">",
"     Treatment of VPBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression of VPBs with antiarrhythmic drugs does not improve either short- or long-term outcomes, and, with some drugs, may actually increase mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Thus, treatment for the suppression of asymptomatic VPBs is",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NONSUSTAINED VENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) is defined as three or more consecutive beats originating below the atrioventricular node, with a heart rate greater than 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    There is some disagreement as to whether 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    represents the upper limit for an accelerated idioventricular rhythm. VT is considered nonsustained if it terminates spontaneously in less than 30 seconds. The incidence of nonsustained VT (NSVT) following MI ranges from 1 to 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In the first 24 to 48 hours after an infarction, NSVT is usually due to abnormal automaticity or triggered activity in the region of ischemia or infarction. In comparison, NSVT that occurs later is more often due to reentry. Thus, the probable mechanism and the prognostic significance of NSVT depend upon the time at which it occurs in relation to infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link&amp;anchor=H11#H11\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'NSVT on monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39702?source=see_link&amp;anchor=H4#H4\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\", section on 'Coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of NSVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with ventricular premature beats (VPBs), antiarrhythmic drugs for the suppression of NSVT is",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"     40",
"    </a>",
"    ]. In the rare case when NSVT is frequent and causes hemodynamic compromise, treatment may be reasonable. In such patients, additional beta blockade or, if necessary,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , may be useful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22952?source=see_link\">",
"     \"Management of nonsustained ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ACCELERATED IDIOVENTRICULAR RHYTHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accelerated idioventricular rhythm (AIVR), which has also been called \"slow ventricular tachycardia,\" arises below the atrioventricular node and has, by definition, a rate between 50 and 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    (",
"    <a class=\"graphic graphic_waveform graphicRef52385 \" href=\"mobipreview.htm?39/57/40856\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/43\">",
"     43",
"    </a>",
"    ]. It may be the result of pacemaker failure, and therefore be an escape rhythm, or it may represent an abnormal ectopic focus in the ventricle that is accelerated by sympathetic stimulation and circulating catecholamines.",
"   </p>",
"   <p>",
"    AIVR occurs in up to 50 percent of patients with acute MI. Some studies have suggested an association with reperfusion following fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/19\">",
"     19",
"    </a>",
"    ]. However, AIVR is neither a sensitive nor very specific marker for successful reperfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\", section on 'Reperfusion arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of AIVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of accelerated idioventricular rhythm (AIVR) are transient and require no treatment. Furthermore, treatment is contraindicated if AIVR is an escape rhythm, since suppression of the ectopic pacemaker focus will result in asystole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"     40",
"    </a>",
"    ]. There are no convincing data linking AIVR to sustained VT or VF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\", section on 'Accelerated idioventricular rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUSTAINED VENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) is defined as three or more consecutive beats originating below the atrioventricular node, with a heart rate greater than 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    There is some disagreement as to whether 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    represents the upper limit for an accelerated idioventricular rhythm. VT is considered sustained if it lasts more than 30 seconds or if it causes instability that requires termination (eg, cardioversion) within 30 seconds.",
"   </p>",
"   <p>",
"    Sustained monomorphic VT (SMVT) in the periinfarction period (ie, within the first 48 hours after the infarct) occurs in approximately 2 to 3 percent of patients with an ST elevation MI (STEMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14,44\">",
"     14,44",
"    </a>",
"    ] and less than 1 percent with a non-STEMI or unstable angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/15\">",
"     15",
"    </a>",
"    ]. SMVT is associated with larger MI size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/44\">",
"     44",
"    </a>",
"    ]. The factors responsible for SMVT differ in the very early (30 minutes) and later phases (6 to 48 hours) of the early post-MI period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation may include palpitations, worsening ischemic symptoms due to the elevated heart rate, and hemodynamic compromise or collapse. Patients with faster tachycardias and worse left ventricular function are less likely to tolerate the arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) is called monomorphic if the QRS complexes are all of one morphology and polymorphic if the QRS morphology varies during an episode (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"mobipreview.htm?28/0/28680\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef80829 \" href=\"mobipreview.htm?20/45/21208\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Monomorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a single, consistent QRS morphology suggests that each beat arises from the same location and activates the ventricle in the same sequence. This uniformity should be present in all 12 electrocardiogram (ECG) leads. As a result, a 12 lead ECG should be obtained in stable patients in order to fully characterize the VT morphology.",
"   </p>",
"   <p>",
"    In the early stage of an evolving infarction (ie, the first 6 to as many as 48 hours), monomorphic VT may result from transient arrhythmogenic phenomena in ischemic and infarcting tissue, such as abnormal automaticity, triggered activity, and reentrant circuits created by heterogeneous conduction and repolarization.",
"   </p>",
"   <p>",
"    SMVT in any other setting is considered a marker of permanent arrhythmic substrate and an increased long-term risk of arrhythmia recurrence and SCD. Because of the physiologic and mechanistic link between SMVT and permanent substrate, it is not clear that SMVT at any point, even early after an MI, should be attributed to transient phenomena. Furthermore, SMVT in the setting of an acute MI may reflect permanent substrate from a prior infarction. As a result, the prognostic significance of SMVT in the early period after an MI is unclear. This issue is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Prognosis after early VT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Polymorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic ventricular tachycardia (VT) is an unusual arrhythmia during acute MI, occurring in 0.3 percent of patients in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/45\">",
"     45",
"    </a>",
"    ]. Like VF and accelerated idioventricular rhythm (AIVR), it is usually due to abnormal automaticity or triggered activity associated with ischemia or reperfusion. When polymorphic VT does occur early after an acute MI, it is typically associated with symptoms or signs of recurrent myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/45\">",
"     45",
"    </a>",
"    ]. The typical features associated with polymorphic VT in other settings are not present (eg, prolonged QT interval in which the polymorphic VT is called torsade des pointe, sinus bradycardia, preceding sinus pauses, or electrolyte abnormalities).",
"   </p>",
"   <p>",
"    Some patients (8 of 434 consecutive patients in one series) do develop typical pause-dependent torsades de pointes that occurs in association with progressive QT interval prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/46\">",
"     46",
"    </a>",
"    ]. This pattern of events occurs during the healing phase of an infarct, usually days 3 to 11, and does not suggest recurrent ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prognosis after early VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early sustained monomorphic ventricular tachycardia (SMVT) is associated with higher in-hospital mortality due to cardiac arrest and possibly to exacerbation of ischemia and extension of the infarct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14,16,41,44,47-49\">",
"     14,16,41,44,47-49",
"    </a>",
"    ]. Whether early SMVT is associated with an increased long-term mortality risk among patients who survive to hospital discharge is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14,16,20,41,47\">",
"     14,16,20,41,47",
"    </a>",
"    ]. Because SMVT usually reflects myocardial scar and permanent arrhythmic substrate, this arrhythmia, even early after an acute MI, may have different implications than nonsustained VT or ventricular fibrillation (VF).",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study compared 162 patients with sustained or nonsustained VT within 48 hours after an acute MI to 2578 post-MI patients without VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/41\">",
"       41",
"      </a>",
"      ]. VT was not associated with an increase in long-term mortality, but the majority of these patients had nonsustained VT (only 28 patients had sustained VT).",
"     </li>",
"     <li>",
"      In the TIMI phase II trial, excluding patients with hypotension or heart failure, 1.9 percent of patients developed sustained VT or VF in the first 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/47\">",
"       47",
"      </a>",
"      ]. These patients had higher in-hospital mortality (20.4 versus 1.6 percent) but, for those who survived 21 days, there was no increase in late mortality compared to patients who did not have ventricular arrhythmias. The implication of these results for patients with monomorphic VT is uncertain, however, because patients with sustained VT and VF were analyzed as a single group.",
"     </li>",
"     <li>",
"      In a study limited to patients with a non-STEMI, SMVT was a significant predictor of increased mortality at both 30 days and six months (adjusted hazard ratio 8 and 5, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the increase in risk was largely due to more deaths in the first 30 days, and the prognostic implications of early VT in patients who survive the post-MI period were not addressed.",
"     </li>",
"     <li>",
"      The APEX AMI trial data was used to evaluate the prognosis of 329 STEMI patients scheduled for PCI who had sustained VT or VF, either before the end of catheterization (early) or after catheterization but before discharge (late) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/20\">",
"       20",
"      </a>",
"      ]. At 90 days the frequency of death was significantly worse in patients with versus those without",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      (23.2 versus 3.6 percent) and outcomes were significantly worse if the",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      was late as opposed to early (33.3 versus 17.2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the relatively small numbers of patients and the combined analysis of patients with VT and VF or nonsustained VT and sustained VT, these studies did not adequately address the long-term prognostic significance of SMVT in the early post-MI setting. As noted above, there are physiologic reasons to suggest that SMVT has different implications than VF or nonsustained VT.",
"   </p>",
"   <p>",
"    Somewhat different findings were noted in the analysis of over 40,000 patients in GUSTO-I, illustrated by the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14\">",
"     14",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef74805 \" href=\"mobipreview.htm?1/54/1902\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar to prior reports, the in-hospital mortality was significantly higher in patients who had SMVT alone (18.6 percent) or SMVT and VF (44.0 percent) compared to those without sustained ventricular arrhythmia (4.2 percent).",
"     </li>",
"     <li>",
"      Among those who survived 30 days, one-year mortality was significantly higher among patients who had SMVT alone (7.1 percent) or SMVT with VF (6.4 percent) compared to those without sustained ventricular arrhythmias (2.7 percent). This finding is in contrast to the earlier studies, in which early VT did not predict worse outcomes among patients who survived the early post-MI period (eg, to hospital discharge).",
"     </li>",
"     <li>",
"      Patients with early VF alone had an increased rate of in-hospital mortality (19.8 percent) but, among those who survived 30 days, the one-year mortality was the same as that in patients without ventricular arrhythmias (approximately 2.8 percent in both groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings support the hypothesis that SMVT and VF have distinct mechanisms and prognoses. The reasons for the discrepancies in the long-term significance of early SMVT between GUSTO-I and the prior studies are uncertain. However, GUSTO-I was larger, analyzed arrhythmias separately, and utilized reperfusion and adjuvant therapies that are closer to contemporary practice than the earlier reports. As a result, some experts consider SMVT, regardless of the temporal relationship to a recent infarction, to reflect fixed substrate for ventricular arrhythmias and therefore to be predictive of a high risk of future arrhythmias and SCD. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Ventricular fibrillation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute treatment of sustained ventricular arrhythmias is discussed in detail separately. The following discussion addresses issues associated with acute MI, and is in broad agreement with 2010 advanced cardiac life support (ACLS) guidelines published by the American Heart Association (AHA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], and with",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Polymorphic VT and unstable monomorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable, poorly-tolerated arrhythmias are a life-threatening emergency that are treated according to established ACLS protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained polymorphic VT, very rapid VT, and pulseless monomorphic VT should be treated with",
"      <strong>",
"       unsynchronized",
"      </strong>",
"      electrical shocks (ie, defibrillation and not cardioversion, which is the delivery of an electrical shock synchronized to the QRS complex). If available, a biphasic waveform defibrillator is preferable since the success rate for defibrillation is higher than with monophasic waveforms. For biphasic defibrillators, the initial shock should be at 120 to 200 joules, with subsequent shocks at the highest available biphasic energy level (200 joules for most devices). For monophasic defibrillators, nonescalating shocks beginning at 360 joules should be used. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=see_link&amp;anchor=H16#H16\">",
"       \"Cardioversion for specific arrhythmias\", section on 'Ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sustained monomorphic VT (in which a distinct QRS complex can be identified) associated with angina, pulmonary edema, or hypotension (systolic blood pressure &lt;90 mmHg) should be treated immediately with",
"      <strong>",
"       synchronized",
"      </strong>",
"      electrical cardioversion using an initial energy of 100 joules. Subsequent shocks at increasing energy can be given as necessary. Brief anesthesia is desirable if hemodynamically tolerable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Stable monomorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when hemodynamically tolerated, sustained VT in the periinfarction period must be treated urgently because of its deleterious effect on cardiac output, possible exacerbation of myocardial ischemia, and the risk of deterioration into ventricular fibrillation. However, if the patient is stable and asymptomatic, cardioversion may be deferred for several minutes, during which an electrocardiogram (ECG) should be obtained and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) initiated. During this time, preparations should simultaneously be made for urgent electrical cardioversion or defibrillation if the patient deteriorates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12-lead ECG can help to distinguish VT from supraventricular tachycardia with aberrant conduction. However, a wide complex tachycardia occurring in the setting of an acute MI should",
"      <strong>",
"       always",
"      </strong>",
"      be considered ventricular in origin unless there is irrefutable evidence to the contrary. Perhaps more important in this setting, the ECG provides information regarding the location of origin of the VT, which may facilitate later diagnostic studies and treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"       \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sustained monomorphic VT that is hemodynamically tolerated and asymptomatic can be treated initially with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ). Synchronized electrical cardioversion with brief anesthesia should be performed if VT persists after the administration of the initial 150 mg of amiodarone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=see_link&amp;anchor=H16#H16\">",
"       \"Cardioversion for specific arrhythmias\", section on 'Ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Recurrent arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent arrhythmias should prompt an urgent evaluation for underlying causes, including recurrent ischemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent SMVT or ventricular fibrillation (VF) that is not due to a reversible cause, such as hypokalemia, ischemia, or heart failure, can be treated with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (150 mg over 10 minutes, followed by an intravenous infusion 1",
"      <span class=\"nowrap\">",
"       mg/min",
"      </span>",
"      for six hours, then 0.5",
"      <span class=\"nowrap\">",
"       mg/min",
"      </span>",
"      for 18 hours) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38857?source=see_link\">",
"       \"Clinical uses of amiodarone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link&amp;anchor=H2#H2\">",
"       \"Major side effects of amiodarone\", section on 'Intravenous amiodarone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with refractory polymorphic VT, aggressive attempts should be made to reduce myocardial ischemia and adrenergic stimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"       40",
"      </a>",
"      ]. These efforts include therapies such as beta blockade, use of an intraaortic balloon pump, and consideration of emergency revascularization.",
"     </li>",
"     <li>",
"      If the patient has refractory polymorphic VT in the setting of bradycardia to a rate less than 60 beats per minute or a long QTc, temporary pacing at a higher rate may be instituted.",
"     </li>",
"     <li>",
"      Electrolytes should be aggressively repleted (serum potassium goal &gt;4.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      and serum magnesium goal &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    that can be administered in a number of ways. The standard method is an infusion of 20",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    until the arrhythmia terminates, hypotension ensues, the QRS is prolonged by more than 50 percent, or a total of 17",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (1.2 g for a 70 kg patient) has been given.",
"   </p>",
"   <p>",
"    The 2010 AHA guidelines give a weak recommendation regarding the use of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for the treatment of recurrent sustained VT, stating it should only be considered for use if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/51\">",
"     51",
"    </a>",
"    ]. However, lidocaine is a relatively safe agent that has no adverse hemodynamic effects and a rapid onset of action, and therefore may be useful in some patients. If lidocaine is used, it should be administered by intravenous push in a dose of 0.5 to 0.75",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    this dose is repeated every 5 to 10 minutes as needed. At the same time, a continuous intravenous lidocaine infusion of 1 to 4",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    is begun. The maximum total dose is 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over one hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     VENTRICULAR FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation (VF) is the most frequent mechanism of sudden cardiac death (SCD). It is a rapid, disorganized ventricular arrhythmia, resulting in no uniform ventricular contraction, no cardiac output, and no recordable blood pressure. The electrocardiogram in VF shows rapid (300 to 400",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    irregular, shapeless QRST undulations of variable amplitude, morphology and interval (",
"    <a class=\"graphic graphic_waveform graphicRef80454 \" href=\"mobipreview.htm?29/47/30455\">",
"     waveform 3",
"    </a>",
"    ). Over time, these wave forms decrease in amplitude. Ultimately, asystole occurs.",
"   </p>",
"   <p>",
"    The majority of episodes of VF occur within the first 48 to 72 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. It is presumably a manifestation of ischemia and is associated with lack of perfusion via the infarct-related artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/47,54\">",
"     47,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Primary and nonprimary VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation (VF) can be further subclassified as primary or nonprimary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary VF refers to VF that occurs early (usually &lt;48 hours post myocardial infarction), and is not associated with recurrent ischemia or heart failure. This category is defined to identify patients who experience VF despite a relatively uncomplicated myocardial infarction (ie, as a primary electrical event).",
"     </li>",
"     <li>",
"      Nonprimary VF refers to all other episodes. VF is more common in patients with myocardial infarctions that are complicated by heart failure or recurrent ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     VF Predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical features that reliably identify the individual patient who is likely to develop ventricular fibrillation (VF) in the periinfarction period. However, retrospective analyses of several clinical trials and a large meta-analysis of both clinical trials and observational series have identified some factors that are associated with an increased risk of early VF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13,15,55,56\">",
"     13,15,55,56",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST elevation myocardial infarction (STEMI) &ndash; In a meta-analysis including 57,158 patients, the presence of ST elevations was the most powerful predictor of primary VF (odds ratio [OR] 3.35 compared to non-STEMI, 95% CI 2.43 to 4.62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/15,56\">",
"       15,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early repolarization &ndash; Early repolarization on baseline ECG appears to be associated with both a greater likelihood of ventricular arrhythmias during an acute coronary syndrome (ACS) as well as a greater likelihood of dying from any ventricular arrhythmias in this setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/38/38505?source=see_link\">",
"       \"Early repolarization\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among a retrospective cohort of 220 patients with STEMI and a baseline ECG available from before the STEMI, patients with early repolarization pre-STEMI were significantly more like to have VF within the first 48 hours post-MI (OR 7.31, 95% CI 2.21-24.14) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a study of 432 cases of sudden cardiac arrest (SCA) confirmed by autopsy to be related to acute coronary syndrome (ACS) along with 532 SCA survivors during ACS, those who died were significantly more like to have early repolarization on a pre-ACS baseline ECG (14.4 versus 7.9 percent for those without early repolarization; adjusted OR 2.15, 95% CI 1.20-3.85) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia &ndash; In the GISSI-2 trial the incidence of VF among patients with a serum potassium &lt;3.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      was nearly twice that seen in patients with a higher serum potassium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13,56\">",
"       13,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypotension &ndash; defined as systolic blood pressure &le;120 mmHg on admission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Larger infarcts (based upon myocardial enzyme levels) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Male sex (OR 1.27, 95% CI 1.12 to 1.43) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      History of smoking (OR 1.26, 95% CI 1.04 to 1.53) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preinfarction angina &ndash; Preinfarction angina may protect against out-of-hospital VF (OR 0.25, 95% CI 0.10 to 0.66, and OR 0.84, 95% CI 0.77 to 0.99 for two different studies, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. This effect is presumably due to ischemic preconditioning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=see_link\">",
"       \"Clinical implications of ischemic preconditioning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the APEX AMI trial of STEMI patients with planned PCI, multivariate analysis identified the following significant predictors of early (prior to the end of cardiac catheterization) VF or sustained VT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pre-PCI Thrombolysis in MI (TIMI) flow grade 0 (HR 2.94, 95% CI 1.93 to 4.47)",
"     </li>",
"     <li>",
"      Inferior infarction (HR 2.16, 95% CI 1.58 to 2.93)",
"     </li>",
"     <li>",
"      Total baseline ST segment deviation (HR 1.39, 95% CI 1.19 to 1.63)",
"     </li>",
"     <li>",
"      Killip Class (",
"      <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"       table 1",
"      </a>",
"      ) greater than I (HR 1.88, 95% CI 1.29 to 2.76)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this same study, the following predictors of late (after the end of catheterization but before discharge) VF or sustained VT were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ST resolution less than 70 percent (HR 3.17, 95% CI 1.60 to 6.28)",
"     </li>",
"     <li>",
"      Total baseline ST deviation (HR 1.43, 95% CI 1.14 to 1.79)",
"     </li>",
"     <li>",
"      Post-PCI TIMI flow less than grade 3 (HR 2.09, 95% CI 1.24 to 3.52)",
"     </li>",
"     <li>",
"      Pre-PCI TIMI flow grade 0 (HR 2.12, 95% CI 1.20 to 3.75)",
"     </li>",
"     <li>",
"      Beta blockers in the first 24 hours (HR 0.52, 95% CI 0.32 to 0.85)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prognosis after early VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of ventricular fibrillation (VF) among patients with an acute MI, if occurring within the first 48 hours, is associated with an increase in early mortality (eg, in-hospital mortality), but little or no increase in mortality at one to two years among patients who survive to hospital discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13,14,47-49,59\">",
"     13,14,47-49,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report from the GISSI-2 trial evaluated the prognostic significance of ventricular arrhythmias in 9720 patients with a first ST elevation MI (STEMI) who were treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13\">",
"     13",
"    </a>",
"    ]. Arrhythmias were characterized as primary VF (occurring in the absence of heart failure or shock), nonprimary VF (all other VF), and VT. Primary VF was further characterized as early (within 6 hours), or late (between 6 and 48 hours). This distinction is in contrast to most other reports, in which the term \"late VF\" usually refers to events that occur more than 48 to 72 hours after the MI. The following findings were noted (",
"    <a class=\"graphic graphic_figure graphicRef69187 \" href=\"mobipreview.htm?33/10/33965\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Both early and late primary VF (ie, all events occurring within the first 48 hours) were associated with a significant increase in in-hospital mortality.",
"     </li>",
"     <li>",
"      The mortality rate from discharge to six months was not affected by primary VF.",
"     </li>",
"     <li>",
"      Mortality from discharge to six months was markedly increased in those with nonprimary VF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in the GUSTO-I trial cited above, which included over 40,000 patients with STEMI who were treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14\">",
"     14",
"    </a>",
"    ]. The 1229 patients with early (first 48 hours) VF alone (ie, without VT) had an increased rate of in-hospital mortality (19.8 versus 4.2 percent in those without sustained ventricular arrhythmia); however, among those who survived 30 days, the one year mortality was the same as that in patients without ventricular arrhythmias (2.7 percent in both groups) (",
"    <a class=\"graphic graphic_figure graphicRef74805 \" href=\"mobipreview.htm?1/54/1902\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Data are more limited in patients with a non-STEMI. In the pooled analysis noted above of patients with non-ST elevation MI or unstable angina, VF was a significant predictor of increased mortality at both 30 days and six months (adjusted hazard ratio 23 and 15, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/15\">",
"     15",
"    </a>",
"    ]. The increase in risk was largely due to more deaths in the first 30 days.",
"   </p>",
"   <p>",
"    Additional information on the prognosis of patients with early VF comes from the APEX trial. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Prognosis after early VT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation (VF) is almost universally lethal if not treated, with very few spontaneous reversions to sinus rhythm. Defibrillation is the definitive therapy for VF. If available, a biphasic waveform defibrillator is preferable since the success rate for defibrillation is higher than with monophasic waveforms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=see_link&amp;anchor=H11#H11\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Monophasic versus biphasic waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2010 AHA guidelines for adult advanced cardiac life support (ACLS) recommended that, for biphasic defibrillators, the initial shock should be at 120 to 200 joules, with subsequent shocks at the highest available biphasic energy level (200 joules for most devices) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/51\">",
"     51",
"    </a>",
"    ]. For monophasic defibrillators, nonescalating shocks beginning at 360 joules should be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following successful reversion to sinus rhythm, patients should be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for 24 to 48 hours. The dosing schedule is similar to that used for sustained VT (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Sustained ventricular tachycardia'",
"    </a>",
"    above). At present, an ICD is not generally appropriate for VF occurring in the first 24 to 48 hours of an acute MI.",
"   </p>",
"   <p>",
"    The approach to VF that persists after three rapid shocks delivered in a row is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Electrical storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical storm is defined as multiple recurrent episodes of ventricular fibrillation (VF). The optimal therapy of this problem in patients with an acute myocardial infarction (MI) is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/376?source=see_link\">",
"     \"Electrical storm and incessant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two approaches warrant comment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One modality that is of benefit is sympathetic blockade. This was illustrated in a report of 49 patients with a recent MI (mean 11 days) who had electrical storm, which was defined as &ge;4",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      episodes per hour or &ge;20 per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/60\">",
"       60",
"      </a>",
"      ]. Compared to 22 patients receiving ACLS-guided antiarrhythmic therapy, those treated with sympathetic blockade (beta blockers in 21 and stellate ganglionic blockade in six) had a lower mortality at one week (22 versus 82 percent). Patients who survived the initial electric storm event did well over the one-year follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radiofrequency catheter ablation may be used as a bailout therapy in patients with refractory electrical storm who may otherwise require cardiac transplantation. The potential efficacy of this approach was illustrated in a report of four patients (out of 2340 seen with an acute MI) with persistent electrical storm despite beta blockers and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/61\">",
"       61",
"      </a>",
"      ]. All episodes were triggered by monomorphic ventricular premature beats (VPBs) with right bundle branch block morphology. Activation mapping of the VPBs identified the sites of earliest activation with Purkinje potentials at the same sites. Six to thirty radiofrequency applications abolished these local potentials and suppressed VPBs in all patients, who subsequently remained free of VT or VF for 5 to 33 months. This surprisingly favorable course following discharge is similar to that described in the preceding report with sympathetic blockade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT OF ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ventricular arrhythmias in the setting of an acute myocardial infarction (MI) should receive aggressive treatment for both the arrhythmia and ischemia. Therapy for ischemia usually includes either primary percutaneous coronary intervention (PCI) or fibrinolysis.",
"   </p>",
"   <p>",
"    The outcomes in patients who are resuscitated from a cardiac arrest in the setting of an ST elevation MI who undergo emergent primary PCI were illustrated in a multicenter series of 186 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCI was successful in 87 percent of cases.",
"     </li>",
"     <li>",
"      Rates of six-month survival and six month survival free of neurological sequelae were 54 and 46 percent, respectively.",
"     </li>",
"     <li>",
"      Predictors of six-month survival were shorter intervals between cardiac arrest and the arrival of first responders and shorter intervals between cardiac arrest and the return of spontaneous circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for the management of ventricular arrhythmias made the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ventricular arrhythmias should be treated aggressively for myocardial ischemia, if present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with evidence of myocardial ischemia that precedes ventricular fibrillation should undergo coronary revascularization for the purpose of reducing the risk of SCD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     LATE ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, patients with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) that occurs after the early acute MI period are considered survivors of sudden cardiac death (SCD). As such, they are treated according to secondary prevention protocols, usually with an implantable cardioverter-defibrillator (ICD). The definition of \"early\" versus \"late\" arrhythmias varies among cardiologists and electrophysiologists, and is also receding with time. Whereas in the past the line was often drawn at 48 to 72 hours, many now consider \"late\" arrhythmias to be those that occur beyond 24 to 48 hours post-MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Late VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Late\" VT (ie, VT that occurs after the first 24 to 48 hours) is most often related to healing of the infarct and may reflect the development of an arrhythmogenic substrate that promotes the development of VT (eg, scar tissue). The associated fibrosis leads to areas of conduction block with interdigitation of viable myocardium; the ensuing slowing of conduction at the border of the infarct can lead to stable reentry circuits and VT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\", section on 'Chronic phase arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late VT is a predictor of a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14,18,65\">",
"     14,18,65",
"    </a>",
"    ]. The following findings were noted in the patients with late ventricular arrhythmia in the GUSTO-I trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The in-hospital mortality was significantly higher in patients who had late sustained VT alone (37.5 percent) or VT and VF (57.0 percent) compared to those without sustained ventricular arrhythmia (4.2 percent).",
"     </li>",
"     <li>",
"      The one-year mortality of 30 day survivors was significantly higher among those who had late VT alone (24.7 percent) compared to those without sustained ventricular arrhythmia (2.7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar adverse effect was noted in the GISSI-3 trial in which late VT occurred in 1 percent of patients between 48 hours and six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/65\">",
"     65",
"    </a>",
"    ]. Late VT was associated with a more complicated in-hospital and six-week posthospital course, a higher incidence of pump failure, atrial arrhythmias, asystole, atrioventricular block, and VF, and a higher mortality at six weeks (35 versus 5 percent without VT, hazard ratio 6.13). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Late VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop sustained VF more than 48 hours after their MI are also thought to be at risk for recurrent ventricular tachyarrhythmias and to have a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14,18,65\">",
"     14,18,65",
"    </a>",
"    ]. Such patients typically receive an ICD as well as revascularization and optimal medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on STEMI gave a class I recommendation to the insertion of an implantable cardioverter-defibrillator (ICD) in patients with hemodynamically significant sustained VT more than two days after an MI, provided that the arrhythmia is not judged to be due to transient or reversible ischemia or reinfarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/12/25795?source=see_link\">",
"       \"Patient information: Ventricular fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13293351\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular arrhythmias, ranging from isolated ventricular premature beats (VPBs) to ventricular fibrillation (VF), are common in the immediate postinfarction period. In the era of early percutaneous coronary intervention and aggressive medical therapy, approximately 25 percent of patients with a non-ST elevation acute coronary syndrome experience ventricular tachycardia (VT) within the initial seven days, an event that portends a significantly greater risk of dying compared to patients without VT. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with asymptomatic VPBs in the peri-infarct period, attempting to suppress these with antiarrhythmic drugs does not improve outcomes, and, with some drugs, may actually increase mortality. Thus, we do not routinely treat asymptomatic VPBs with antiarrhythmic medications during the peri-infarct period. (See",
"      <a class=\"local\" href=\"#H11046610\">",
"       'Ventricular premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with asymptomatic nonsustained ventricular tachycardia (NSVT) in the peri-infarct period, suppression with antiarrhythmic drugs has not been shown to improve outcomes. Thus, we do not routinely treat asymptomatic NSVT with antiarrhythmic medications during the peri-infarct period. However, in the rare case when NSVT is frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      causes hemodynamic compromise, treatment with additional beta blockade or, if necessary, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , may be useful. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonsustained ventricular tachycardia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22952?source=see_link\">",
"       \"Management of nonsustained ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VF is the most frequent mechanism of sudden cardiac death, with the majority of VF occurring within the first 48 to 72 hours after the onset of symptoms. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Ventricular fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ST elevation myocardial infarction (STEMI) treated with fibrinolysis, the incidence of sustained VT or VF is approximately 10 percent, with 80 to 85 percent occurring in the first 48 hours. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fibrinolytic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with STEMI treated with primary percutaneous coronary intervention (PCI), VT or VF occurs in approximately 6 percent, with 85 percent occurring in the first 48 hours. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Primary PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following non-STEMI, patients have a much lower incidence of sustained VT or VF (2 percent), with the majority of these arrhythmias occurring after 72 hours. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Non-ST elevation MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of VF among patients with an acute MI, if occurring within the first 48 hours, is associated with an in-hospital mortality rate of approximately 20 percent. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prognosis after early VF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop early VT (within 48 hours) have markedly higher rates of 30-day mortality (as high as 40 percent mortality compared to 2 to 4 percent mortality in those without VT). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis after early VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In accordance with the 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA/ESC",
"      </span>",
"      guidelines, patients with sustained, hemodynamically unstable ventricular arrhythmias should be treated aggressively for myocardial ischemia, if present, and should undergo coronary revascularization for the purpose of reducing the risk of sudden cardiac death. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment of ischemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/1\">",
"      Lown B. Sudden cardiac death: the major challenge confronting contemporary cardiology. Am J Cardiol 1979; 43:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/2\">",
"      Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 1992; 85:I2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/3\">",
"      Pell S, Fayerweather WE. Trends in the incidence of myocardial infarction and in associated mortality and morbidity in a large employed population, 1957-1983. N Engl J Med 1985; 312:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/4\">",
"      Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999; 100:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/5\">",
"      Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/6\">",
"      Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/7\">",
"      Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/8\">",
"      O'Doherty M, Tayler DI, Quinn E, et al. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J (Clin Res Ed) 1983; 286:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/9\">",
"      Harkness JR, Morrow DA, Braunwald E, et al. Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial). Am J Cardiol 2011; 108:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/10\">",
"      Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975; 51:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/11\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/12\">",
"      Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/13\">",
"      Volpi A, Cavalli A, Santoro L, Negri E. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. Am J Cardiol 1998; 82:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/14\">",
"      Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998; 98:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/15\">",
"      Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002; 106:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/16\">",
"      Henkel DM, Witt BJ, Gersh BJ, et al. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. Am Heart J 2006; 151:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/17\">",
"      Thompson CA, Yarzebski J, Goldberg RJ, et al. Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester Heart Attack Study. Am Heart J 2000; 139:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/18\">",
"      Sarter BH, Finkle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996; 28:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/19\">",
"      Gorgels AP, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1988; 61:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/20\">",
"      Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009; 301:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/21\">",
"      Dekker LR, Bezzina CR, Henriques JP, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 2006; 114:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/22\">",
"      Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006; 114:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/23\">",
"      Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977; 297:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/24\">",
"      Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981; 64:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/25\">",
"      Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984; 54:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/26\">",
"      Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/27\">",
"      Prognostic importance of premature beats following myocardial infarction. Experience in the coronary drug project. JAMA 1973; 223:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/28\">",
"      Andresen D, Bethge KP, Boissel JP, et al. Importance of quantitative analysis of ventricular arrhythmias for predicting the prognosis in low-risk postmyocardial infarction patients. European Infarction Study Group. Eur Heart J 1990; 11:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/29\">",
"      Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/30\">",
"      Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 117:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/31\">",
"      Moss AJ, Davis HT, DeCamilla J, Bayer LW. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 1979; 60:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/32\">",
"      Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/33\">",
"      Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/34\">",
"      Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base. Circulation 1993; 88:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/35\">",
"      Statters DJ, Malik M, Redwood S, et al. Use of ventricular premature complexes for risk stratification after acute myocardial infarction in the thrombolytic era. Am J Cardiol 1996; 77:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/36\">",
"      Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996; 27:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/37\">",
"      Larosa C, Infusino F, Sgueglia GA, et al. Effect of primary percutaneous coronary intervention versus thrombolysis on ventricular arrhythmias and heart rate variability in acute myocardial infarction. Ital Heart J 2005; 6:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/38\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/39\">",
"      Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/40\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/41\">",
"      Eldar M, Sievner Z, Goldbourt U, et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med 1992; 117:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/42\">",
"      Heidb&uuml;chel H, Tack J, Vanneste L, et al. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. Circulation 1994; 89:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/43\">",
"      Rothfeld EL, Zucker IR, Parsonnet V, Alinsonorin CA. Idioventricular rhythm in acute myocardial infarction. Circulation 1968; 37:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/44\">",
"      Mont L, Cinca J, Blanch P, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol 1996; 28:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/45\">",
"      Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/46\">",
"      Halkin A, Roth A, Lurie I, et al. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. J Am Coll Cardiol 2001; 38:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/47\">",
"      Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/48\">",
"      Tofler GH, Stone PH, Muller JE, et al. Prognosis after cardiac arrest due to ventricular tachycardia or ventricular fibrillation associated with acute myocardial infarction (the MILIS Study). Multicenter Investigation of the Limitation of Infarct Size. Am J Cardiol 1987; 60:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/49\">",
"      Goldberg RJ, Gore JM, Haffajee CI, et al. Outcome after cardiac arrest during acute myocardial infarction. Am J Cardiol 1987; 59:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/50\">",
"      Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/51\">",
"      Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/52\">",
"      Klein RC, Machell C, Rushforth N, Standefur J. Efficacy of intravenous amiodarone as short-term treatment for refractory ventricular tachycardia. Am Heart J 1988; 115:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/53\">",
"      Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/54\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/55\">",
"      Gheeraert PJ, Henriques JP, De Buyzere ML, et al. Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery. J Am Coll Cardiol 2001; 38:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/56\">",
"      Gheeraert PJ, De Buyzere ML, Taeymans YM, et al. Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic review and meta-analysis. Eur Heart J 2006; 27:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/57\">",
"      Naruse Y, Tada H, Harimura Y, et al. Early repolarization is an independent predictor of occurrences of ventricular fibrillation in the very early phase of acute myocardial infarction. Circ Arrhythm Electrophysiol 2012; 5:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/58\">",
"      Tikkanen JT, Wichmann V, Junttila MJ, et al. Association of early repolarization and sudden cardiac death during an acute coronary event. Circ Arrhythm Electrophysiol 2012; 5:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/59\">",
"      Jensen GV, Torp-Pedersen C, Hildebrandt P, et al. Does in-hospital ventricular fibrillation affect prognosis after myocardial infarction? Eur Heart J 1997; 18:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/60\">",
"      Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/61\">",
"      B&auml;nsch D, Oyang F, Antz M, et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation 2003; 108:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/62\">",
"      Garot P, Lefevre T, Eltchaninoff H, et al. Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. Circulation 2007; 115:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/63\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/64\">",
"      de Bakker JM, van Capelle FJ, Janse MJ, et al. Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation 1993; 88:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/10/30890/abstract/65\">",
"      Volpi A, Cavalli A, Turato R, et al. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base. Am Heart J 2001; 142:87.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1060 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30890=[""].join("\n");
var outline_f30_10_30890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13293351\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3618811\">",
"      Pre-fibrinolytic era versus PCI era",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Non-ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Temporal trends",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FAMILIAL PREDISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11046610\">",
"      VENTRICULAR PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11046617\">",
"      Pre-thrombolytic era",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11046624\">",
"      Thrombolytic era",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11046631\">",
"      Primary PCI era",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11047053\">",
"      Treatment of VPBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NONSUSTAINED VENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of NSVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACCELERATED IDIOVENTRICULAR RHYTHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of AIVR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUSTAINED VENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Polymorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prognosis after early VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Polymorphic VT and unstable monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Stable monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Recurrent arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      VENTRICULAR FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Primary and nonprimary VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      VF Predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prognosis after early VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Electrical storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT OF ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      LATE ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Late VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Late VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13293351\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1060|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/54/1902\" title=\"figure 2\">",
"      Post MI survival in patients with VT or VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/10/33965\" title=\"figure 3\">",
"      Primary VF outcome GISSI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1060|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/59/4027\" title=\"table 1\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1060|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/0/28680\" title=\"figure 1\">",
"      ECG Monomorphic VT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?39/57/40856\" title=\"waveform 1\">",
"      ECG Accelerated idioventricular rhythm tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?20/45/21208\" title=\"waveform 2\">",
"      ECG Polymorphic VT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/47/30455\" title=\"waveform 3\">",
"      ECG Ventricular fibrillation tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/38/38505?source=related_link\">",
"      Early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/376?source=related_link\">",
"      Electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/12/25795?source=related_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41769?source=related_link\">",
"      Prognosis after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39702?source=related_link\">",
"      Prognosis of nonsustained VT in the presence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_10_30891="Counsel prevention HBV recs";
var content_f30_10_30891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for counseling and prevention of transmission of hepatitis B from individuals with chronic hepatitis B virus (HBV) infection:",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Carriers should be counseled regarding prevention of transmission of HBV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sexual and household contacts of carriers who are negative for HBV seromarkers should receive hepatitis B vaccination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Newborns of HBV-infected mothers should receive HBIG and hepatitis B vaccine at delivery and complete the recommended vaccination series",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Persons who remain at risk for HBV infection such as infants of HBsAg-positive mothers, health care workers, dialysis patients, and sexual partners of carriers should be tested for response to vaccination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Postvaccination testing should be performed at 9 to 15 months of age in infants of carrier mothers and one to two months after the last dose in other persons",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Follow-up testing of vaccine responders is recommended annually for chronic hemodialysis patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abstinence or only limited use of alcohol is recommended in hepatitis B carriers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persons who are positive only for anti-HBc and who are from a low endemic area with no risk factors for HBV should be given the full series of hepatitis B vaccine",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lok, ASF, McMahon, BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30891=[""].join("\n");
var outline_f30_10_30891=null;
var title_f30_10_30892="Evaluation hypotension by TEE";
var content_f30_10_30892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of hypotension by transesophageal echocardiography",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        EDA",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        FAC",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        PVF",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        E/A",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        SWMA",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemia",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        S &gt; D",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        +/ -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        Variably &uarr;",
"       </td>",
"       <td>",
"        S &gt; D",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiogenic",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;&darr;",
"       </td>",
"       <td>",
"        S &lt; D",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        + /-",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RV infarct",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        NL/&darr;",
"       </td>",
"       <td>",
"        S &gt; D",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &darr;RVEF &uarr;RV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MR",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        SFR",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        + /-",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pul embolism",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        S &gt; D",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &darr;RVEF &uarr;RV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tamponade",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        Resp var*",
"       </td>",
"       <td>",
"        Resp var*",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &darr;RVEF, RV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EDA: left ventricular end-diastolic area; FAC: LV fractional area change; PVF: pulmonary venous flow; E/A: ratio of early to late mitral inflow; SWMA: LV segmental wall motion abnormalties; RVEF: right ventricular ejection fraction; RA: right atrium; S: systolic flow; D: diastolic flow; SFR: systolic flow reversal; MR: mitral regurgitation.",
"     <br>",
"      * Reciprocating respiratory changes in LA, LV dimensions.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30892=[""].join("\n");
var outline_f30_10_30892=null;
var title_f30_10_30893="Types post-acute care facil";
var content_f30_10_30893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Capabilities of types of post-acute care hospital facilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Acute care hospitals",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       IRFs and LTACs",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Medicare-certified facilities (SNFs, TCUs, subacute)",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Extended care facilities (ECFs) Medicaid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Hospital-based (TCU)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Community-based subacute and SNF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <strong>",
"        Response to resuscitation*",
"       </strong>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Rapid",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Rapid",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Rapid",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Slow",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Slow",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Equipment and trained staff",
"      </td>",
"      <td class=\"sublist1\">",
"       Equipment and trained staff",
"      </td>",
"      <td class=\"sublist1\">",
"       Hospital level",
"      </td>",
"      <td class=\"sublist1\">",
"       Limited equipment and trained staff, \"911\"",
"      </td>",
"      <td class=\"sublist1\">",
"       Limited equipment and trained staff, \"911\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <strong>",
"        Access to complex diagnostic/therapeutic modalities",
"       </strong>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Laboratory, imaging, IR",
"      </td>",
"      <td class=\"sublist1\">",
"       X-ray, ultrasound, laboratory on site",
"      </td>",
"      <td class=\"sublist1\">",
"       Hospital level",
"      </td>",
"      <td class=\"sublist1\">",
"       Off-site X-ray and laboratory",
"      </td>",
"      <td class=\"sublist1\">",
"       Off-site X-ray and laboratory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <strong>",
"        Availability of subspecialty consultants",
"       </strong>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Full range, subspecialties",
"      </td>",
"      <td class=\"sublist1\">",
"       Psych, Pain, Ortho, Neuro, PM&amp;R;",
"      </td>",
"      <td class=\"sublist1\">",
"       Hospital level",
"      </td>",
"      <td class=\"sublist1\">",
"       Psych, Hospice, Ophthalmology, Dental, Podiatry",
"      </td>",
"      <td class=\"sublist1\">",
"       Psych, Hospice, Ophthalmology, Dental, Podiatry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <strong>",
"        Intensity of RN services",
"       </strong>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate-low",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate-low",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        12 hours/",
"       </p>",
"       <p>",
"        patient/day (ICU)",
"       </p>",
"      </td>",
"      <td class=\"sublist1\">",
"       <p>",
"        5-6 hours/",
"       </p>",
"       <p>",
"        patient/day",
"       </p>",
"      </td>",
"      <td class=\"sublist1\">",
"       <p>",
"        3-4 hours/",
"       </p>",
"       <p>",
"        patient/day",
"       </p>",
"      </td>",
"      <td class=\"sublist1\">",
"       <p>",
"        2-4 hours/",
"       </p>",
"       <p>",
"        patient/day",
"       </p>",
"      </td>",
"      <td class=\"sublist1\">",
"       <p>",
"        0.5-2 hours/",
"       </p>",
"       <p>",
"        patient/day",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <strong>",
"        Intensity of MD services",
"       </strong>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       24 hour, on site MD",
"      </td>",
"      <td class=\"sublist1\">",
"       24 hour, on site MD",
"      </td>",
"      <td class=\"sublist1\">",
"       24 hour, on site MD",
"      </td>",
"      <td class=\"sublist1\">",
"       2-3x/wk, rarely daily",
"      </td>",
"      <td class=\"sublist1\">",
"       1x/mo, rarely daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <strong>",
"        Intensity of rehabilitation services",
"       </strong>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       High",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Moderate",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       All modalities",
"      </td>",
"      <td class=\"sublist1\">",
"       All modalities",
"      </td>",
"      <td class=\"sublist1\">",
"       Most modalities",
"      </td>",
"      <td class=\"sublist1\">",
"       PT, OT, speech, rarely PM&amp;R;, low complexity",
"      </td>",
"      <td class=\"sublist1\">",
"       PT, OT, speech, maintenance",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IRF: inpatient rehabilitation facility; LTAC: long term acute care hospital; SNF: skilled nursing facility; TCU: transitional care unit; ECF: extended care facility; IR: interventional radiology; PM&amp;R: physical medicine and rehabilitation; PT: physical therapy; OT: occupational therapy.",
"     <br>",
"      * Response to resuscitation can be interpreted as a proxy for the facility's ability to cope with clinically unstable patients.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30893=[""].join("\n");
var outline_f30_10_30893=null;
var title_f30_10_30894="Survival after transplant PAH";
var content_f30_10_30894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Survival after lung transplantation for recipients with primary pulmonary hypertension (PPH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival after lung transplantation for recipients with primary pulmonary hypertension for transplantations performed between January 1990 and June 2005, stratified by procedure type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart-Lung transplant report-2007. J Heart Lung Transplant 2007; 26:787. Copyright &copy;2007 Elsevier.",
"     <br>",
"      <br>",
"       For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled \"Adult lung transplantation Diagnosis: Idiopathic arterial pulmonary hypertension\" at: file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30894=[""].join("\n");
var outline_f30_10_30894=null;
var title_f30_10_30895="Endoscopic component separation technique balloon insertion";
var content_f30_10_30895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Endoscopic component separation technique balloon insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A balloon dissector is inserted in the midaxillary line and infalted with saline. The inflated balloon hydrodissects a vertical pocket in the subcutaneous tissue. The space is gently insufflated for exposure and two trochars are inserted under direct vision to continue the dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Lowe JB, Garza JR, Bowman JL, et al. Endoscopically assisted \"components separation\" for closure of abdominal wall defects. Plast Reconstr Surg 2000; 105:720.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_10_30895=[""].join("\n");
var outline_f30_10_30895=null;
